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This project focuses on Using Qβ VLPs to package, protect, and deliver recombinantly 
produced RNAs. The ultimate goal is to develop an RNA interference (RNAi) delivery 
platform to inhibit gene expression that is spontaneously assembling and scalable for 
potential medical applications. Preliminary studies suggested that this platform is 
amenable to efficient packaging of functional RNA and, most recently, simultaneous 
packaging with DNA plasmid. The principle goals were to i) determine the prevailing 
factors that affect efficient RNA assembly within VLPs, ii) demonstrate spontaneously 
intracellular uptake of VLP-cargos, iii) design a RNAi scaffold for one step in vivo VLP-
RNA assembly, iv) deliver VLP-RNAi to human cancer cells for gene knockdown and 
expression, and vi) decorate RNA-containing VLP with polymer for plasmid delivery. 
 
I have made significant progress in solving the VLP-RNA assembly problem and have 
discovered parameters that allow optimization of RNA production, packaging density and 
purity within Qβ VLPs. For the first time, to our knowledge, we can obtain Qβ VLP-
RNAs containing a high density of homogeneous RNA. I also demonstrated that VLP 
offer substantial protection to packaged RNA against various types of metal-mediated 
cleavage. 
 
I devised an RNAi scaffold that is a general utility single RNA molecule chimera that 
contains a functional RNA duplex with paired silencing and carrier sequences linked by 
and stabilized by a RNA stem-loop. The scaffold is a single molecule of RNA with the 
hairpin on the 5’ end that confers affinity for the viral coat protein (CP). The free 3’ end 
 xv 
of the scaffold allows for recognition by Dicer and transfer of the processed RNA to 
Argonaute (Ago). Silencing sequences can include mature miRNAs and siRNAs, and can 
target any mRNA. 
 
I claim a single-step and scalable method for recombinantly produced RNAs and folding 
of functional RNAs in a novel RNAi scaffold, packaged within VLPs. The VLP-RNAi 
assembles in E. coli, or other expression systems, upon co-expression of CP and the 
RNAi scaffold. The annealing of the scaffold to form functional RNAs is intramolecular, 
because the scaffold is a single RNA molecule, and therefore annealing is concentration 
independent and is efficient in the in vivo assembly environment.  
 
I introduced a VLP surface decorating method using cationic polymers that is generally 
applicable, scalable, spontaneously assembling at the level of molecules, deliverable, 
targetable and potential orally available. Capsid protein and functional RNA or protein 
co-produce and co-assemble to produce VLP assembles in vivo. With this decorating 
method, VLPs can attract plasmid DNA on the exterior of the VLP surface. The method 
is amenable to packaging of a broad array of plasmid DNA and negatively charged drug 
molecules. 
 
The ultimate goal is to deliver multifunctional VLPs against brain tumor growth in mice. 
The new RNAi scaffold we designe can carry different target siRNAs and self-assemble 
into stable RNA nanoparticles. The RNA nanoparticles with Qβ hp can then be 
encapsulated into Qβ VLP. We believe this multifunctional VLPs platform has potential 
 xvi 
to overcome impediments as mentioned earlier and is well suited for nucleic acid-based 
tools. 
 
All together, this dissertation expands our current knowledge on RNA packaging in VLPs 
and demonstrates proof of concept of combining VLPs with novel RNAi scaffold and 




1.1 Qβ Virus-Like Particles and Current Applications 
 General background of Qβ virus-like particles 1.1.1
Qβ Virus-like particles (VLPs) are macromolecule self-assemblies, composed of 180 
copies of a 14.4 kDa coat proteins that form three-dimensional structures resembling 
native single-stranded RNA bacteriophage Qβ viruses at the nanometer level. The coat 
protein monomer forms Qβ dimer spontaneously under physiological conditions (Figure 
1.1-1).1,2 Dimers further assemble into pentamer and hexamer by disulfide bonds and 
hydrogen bond interactions that eventually form Qβ VLP (Figure 1.1-2). The size of Qβ 
VLPs ranges from 25 to 30 nm with icosahedral structure and have pores of around 14 Å 
and 7 Å in diameter.1 Although the morphology of Qβ VLPs is similar to infectious 
viruses, they are benign and noninfectious due to the absence of viral nucleic acid. Qβ 
VLPs have shown substantial tolerance against hostile organic solvents,2,3 extreme pH 
conditions,4 and high temperature stress,5,6 due to their inherent structural stability. Qβ 
VLPs have also been gaining a lot of attention in recent years because of their 
biocompatibility, biodegradability, and low toxicity.7,8 Nowadays, Qβ VLPs can be 
obtained from different recombinant organisms. The genes encoding viral coat protein are 
cloned, recombinantly expressed, and self-assembled in microbial, yeast, and cell-free 
protein synthesis reaction.4,9,10 
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Figure 1.1-1 The structure of (a) Qβ coat protein monomer and (b) noncovalent coat 
protein dimer (PDB: 1qbe). 
Figure 1.1-2 Self-Assembly of Qβ VLP shown in cartoon representation. (a and b) 
Qβ dimers self-assemble into hexamer and pentamer by the disulfide bonds in 










 Surface modification of Qβ VLPs 1.1.2
 Qβ VLPs have potential for several biomedical applications. The composition and highly 
ordered repetitive structure of Qβ VLPs allow conventional protein conjugation 
strategies.11,12 For example, VLPs, which bear lysines, glutamic or aspartic acids, 
cysteines, and tyrosines on their surface, can be conjugated covalently with ligand and 
small molecules to generate chimeric VLPs in vitro (Figure 1.1-3).8,13 Chemical 
modification allows the conjugation of VLPs to multiple molecules, such as antigens, 
peptides, fluorescent dyes, protein, and complex carbohydrates.14 The surface 
functionalization of VLP with different functional molecules has been integrated to 
produce multifunctional bio-nanoparticles that may be used for drug delivery, 
bioimaging, and cell targeting.15  
 
 
Figure 1.1-3 Conventional bioconjugation strategies targeting the functional groups 
of natural amino acids of Qβ VLPs. 
 
In addition to the chemical modification, viral coat proteins can tolerate extensive genetic 
modification. Heterologous peptides are capable of being inserted into coat protein using 
recombinant nucleic acid technique.16,17 Introducing single or multiple mutations into the 
sequence of the Qβ coat protein gene allow production of chimeric VLPs in distinct 
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structural forms.2 In addition, dual expression of Qβ coat protein and Qβ coat protein-
peptide fusion in E. coli results in the assembly of hybrid VLPs. It is the most common 
method for displaying proteinaceous ligands on the exterior surface of VLPs. (Figure 1.1-
4).18,19 However, genetic insertion of long heterologous peptides (more than 20 amino 
acids) may lead to failed self-assembly.  
 
Figure 1.1-4 Genetic insertion of epidermal growth factor on the exterior surface of 








 In vitro and in vivo packaging of cargo into Qβ VLPs 1.1.3
In addition to the applications of exterior surface modification of VLPs, packaging 
capacity of VLPs has lately generated interest as a way to develop of new drug delivery 
vehicles that can encapsulate nucleic acids,20-22 proteins,23,24 and small molecules.25,26 
VLPs have been successfully employed as multifunctional bio-nanoparticles to conjugate 
targeting ligands and selectively deliver quantum dots, chemotherapeutic drugs, siRNA 
molecules, and protein toxins to mammalian cells (Figure 1.1-5).15 The major problems 
of using VLPs as nanocarriers is based on in vivo expression of viral coat protein and in 
vitro self-assembly and encapsulation of cargo. This in vitro packaging approach has a 
number of impediments, such as coat protein re-assembly difficulties, and inefficient 
encapsulation. Thus, a general, efficient and robust strategy for the in vivo production of 
protein-filled or RNA-filled VLPs has been developed to overcome the inconveniences of 
in vitro self-assembly and encapsulation of cargos.  
 
In comparison to in vitro packaging method, in vivo packaging approaches are attractive 
for the following reasons: (i) All cargos are produced with VLPs simultaneously in vivo. 
(ii) Decreased chance of failure to fold cargos (protein and RNA) into native structure. 
(iii) Cargos expressed in recombinant organisms are selectively encapsulated into 
particles within cells. (iv) Coat proteins can efficiently self-assemble to form VLP-cargo 
complexes. (v) VLPs offer in vivo packaged cargos substantial protection from thermal 
inactivation, enzyme degradation, and non-specific protein adsorption. Finn, et al, has 
demonstrated the RNA-mediated packaging method to encapsulate active enzymes within 
VLPs in vivo (Figure 1.6).23,24 Recently, Ponchon, et al, exhibited encapsulation of tRNA 
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fusions in VLPs to form RNA-protein complexes using E. coli.21 In vivo packaging may 
increase the yield of fragile RNA molecules and proteins, enable rapid purification of 
stabilized recombinant RNA molecules, and provide new delivery tools for targeted 
cancer therapy.     
 
Figure 1.1-5 Using conjugation strategies and in vitro assembly method on MS2 
VLPs to selectively deliver quantum dots, anticancer drugs, siRNA molecules to 




Impediments to broadly applicable RNA-based therapeutics remain. Cellular uptake is 
inhibited by the high anionic charge of RNA. Chemical and biological stability of RNA is 
low.27,28 RNA production on large scales by in vitro RNA transcription 29 or solid-phase 
synthesis 30 is problematic.31,32 The packaging of RNA by protein(s) in coupled RNA 
production/packaging systems in vivo may be effective for overcoming at least a subset 
of these challenges. RNA expression in vivo 33-35 employs recombinant viral RNAs 
containing polymerase promoters upstream from target sequences.  
 
Coupled RNA production/protein packaging are achievable because non-viral RNA can 
be encapsulated in VLPs upon co-expression of RNA and CP in systems such as E. coli.36 
RNA packaging into VLPs is promoted by incorporation of RNA hairpins with high 
affinity for CP.37,38 These hairpins, with specific Qβ or MS2 sequences, are derived from 
the genomes of the viral RNAs. CP binds to the viral RNA hairpins during virus 
assembly in vivo.39 Secondary structure also promotes viral assembly; RNA stem-loops 
promote capsid formation.40 Biological stability of RNA is increased by scaffold systems 
in which target RNA is fused to stable folds such as 5S rRNA or tRNA. These fusions 







Figure 1.1-6 (a) Using dual plasmid strategies to encapsulate green fluorescent 
protein inside Qβ VLPs. (b) Chemically derivatized fluorescent VLP were 











1.2 RNA Interference 
 General background of RNAi 1.2.1
The discovery of double stranded RNA (dsRNA) inducing repression of endogenously 
expressed protein in Caenorhabditis elegans was one of the most important discoveries in 
cell biology.47 This unique gene silencing effect was later shown to be carried out in 
mammalian cells transfected with 21 nucleotide (nt) RNA duplexes 48 known as small 
interfering RNAs (siRNAs). This biological mechanism, termed RNA interference 
(RNAi), has potential utility in fundamental research, in drug discovery, and in treatment 
of genetic disorders. In 2004, introduction of a siRNA molecule by intravitreal injection 
demonstrated great success in targeting the vascular endothelial growth factor (VEGF) 
mRNA. In recent years, using RNAi based tools for therapeutic applications has been 
applied to a wide range of human diseases, including genetic diseases, cancers, and viral 
infections.49,50 An intriguing property of RNAi-based tools is the specificity of target 
gene knockdown, taking advantage of base-pairing interactions for target recognition. 
The main types of RNA molecules involved in RNAi are microRNAs (miRNAs) and 
siRNAs. 
 
 The miRNA processing pathway 1.2.2
miRNAs are naturally occurring biological molecules. Numerous miRNAs have been 
identified in insects,51 plants,52 and humans.53 In contrast to siRNAs, miRNAs are usually 
~21-25 nt asymmetric RNA duplexes. They are partially complementary to the mRNA 
target usually located within the 3’ untranslated region (UTR) to mediate post-
transcriptional gene silencing. miRNAs require extensive processing from their 
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transcribed precursors in order to form mature RISC, which inhibits translation initiation 
(Figure 1.2-1, right).54,55 First, primary microRNAs (pri-miRNAs) are expressed from 
genomic DNA in nucleus,56,57 and are processed by microprocessor complex (Drosha and 
DGCR8) into ~70 nt precursor miRNAs (pre-miRNAs).58,59 The pre-miRNAs are further 
exported to cytoplasm by exportin 5. Dicer associates with trans-activation response 
RNA-binding protein (TRBP) and protein kinase RNA activator (PACT) processes 
exported pre-miRNAs into miRNA duplexes. miRNA duplex is then loaded into 
Argonaute (Ago) protein-containing complex to form precursor RNAi-induced silencing 
complex (pre-RISC). To form activated RISC, one strand of the duplex, where it serves 
as “passenger strand” is removed. Finally, the “guide strand” of the duplex in activated 
RISC directs the complex to target gene and inhibits protein translation. RISC dissociates 
from cleaved mRNA and is recycled for additional rounds of gene silencing. Synthetic 
siRNA and short hairpin RNA (shRNA), which mimics Dicer substrates, can be loaded 
into Dicers and allows RISC complex to trigger site-specific cleavage.60,61  
  
 The siRNA processing pathway 1.2.3
Chemically synthesized siRNA is one of the most common approaches to effectively 
down-regulating gene expression through the RNAi mechanism. siRNAs are ~21-23 nt 
duplexes that mimic the Dicer products. In general, siRNAs show perfect complementary 
to the target sequences. Once exogenously supplied siRNAs associate with RNAi-
induced silencing complex (RISC), one strand serves as “guide strand” that directs 
mature RISC to mediate site-specific cleavage of mRNA, and, hence, inhibition of 
protein translation (Figure 1.2-1, right).62 Newly published results show “dicer-ready 
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siRNA” is 100-fold more potent than conventional siRNAs. Dicer-ready siRNAs are 
double stranded RNA, 25-27 nt in length. On administration, these longer version siRNA 
moleculess are readily processed by dicer into siRNAs, and then initiates a RNAi 
pathway as mentioned in the previous section.60  
 
 Anticancer and antiviral activities 1.2.4
Currently, RNAi-based tools are also considered as a potential therapeutic candidate 
directed against common oncogenes in human cancer.63-65 The use of viral vector 
expressing siRNA has successfully inhibited tumor progression in mice models.66 
Additional findings have suggested that RNAi may be considered as one of innate 
antiviral defense mechanisms. RNAi has recently been developed as a potential antiviral 
therapeutic agents. For example, several specific human immunodeficiency virus (HIV) 
mRNAs and HIV genome have been effectively degraded via RNAi-mediated cleavage.50 
Promising results have shown that RNAi can inhibit various pathogenic viruses in vivo, 
including Nodamura virus (NoV),67 human respiratory syncytial virus (RSV),68 and 





Figure 1.2-1 The RNAi processing pathway overview in mammals. Left: miRNA 











1.3 RNA-Based tools delivery strategies 
Although numbers of RNAi-based therapeutic agents are involved in ongoing clinical 
studies (Table 1.3-1), numerous barriers, including biological and chemical stability and 
intracellular uptake of RNA must be overcome before RNAi-based tools become an 
effective strategy for gene therapy. Owing to the high anionic charge of the RNA 
backbone, and low inherent stability of RNA, small molecules, polymers, lipids, peptides, 
aptamers and proteins are most commonly used for effective delivery and reinforcing 
stability of RNAi therapeutics.74   
Table 1.3-1 Clinical trials for RNAi-based therapeutics* 
 
 
 *From ClinicalTrials.gov 












Bevasiranib Diabetic macular 
edema (DME) 
VEGF Completed, II Opko Health, Inc 
PF-655 AMD; DME RTP801 Active, I Quark Pharm., 
Inc 
Cancers CALAA-01 Solid tumor RRM2 Active, I Calando Pharm. 
Atu027 Metastatic solid 
malignancies 
PKN3 Active, I Silence 
Theraputics 



















Active, 0 City of Hope 
Medical 
Center/Benitec 
SPC3649 Hepatitis C virus 
(HCV) 






Active, II Alnylam Pharm 
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 Non-viral  vector delivery systems 1.3.1
Small molecules, polymers, lipids, peptides, aptamers and antibodies have been employed to 
facilitate RNA-based tools delivery (Figure 1.3-1).75 The most common carriers are lipid 
nanoparticles (LNPs) which have shown encouraging results in clinical trials with solid tumor 
and hypercholesterolemia.76,77 It is striking that using the same RNAi delivery approach can 
provide substantial protection against Ebola virus in non-human primates.78 Recent studies have 
developed aptamer-siRNA chimeras capable of selectively delivering functional siRNA into 
prostate cancer cells and HIV-infected cells and demonstrated more potent inhibition.79,80 
Cationic polymers (e.g., polyaminoester (PAS), poly-L-lysine (PLL), and polyethyleneimine 
(PEI)) have also been widely used to deliver anionic DNA plasmid or siRNA molecules through 
electrostatic interactions.81,82 In addition, amine functional groups in cationic polymers allow for 
covalent conjugation of targeting ligands, small molecules, and polymers to increase specificity 
and potency. These polymer-based systems protect encapsulated RNA from degradation in 










Figure 1.3-1 Common strategies for RNA-based tool delivery. Figure adapted from Järver 





 Viral  vector delivery systems 1.3.2
Another approach for delivering of nuclieci acid into cells is to use non-pathogenic viruses for 
DNA plasmid delivery. Viruses that have been used include adeno-associated viruses (AAV), 
adenoviruses, and lentivirus (Figure 1.3-2).86-88 Targeting RNA molecules (e.g., shRNA or 
miRNA) are produced in virally infected cells by encapsulated DNA plasmid and are processed 
into siRNA which leads to gene silencing. In general, this system shows greater efficiencies for 
cellular delivery and gene expression, compared to non-viral mediated systems 81. This viral 
vector delivery system has several limitations, such as plasmid DNA packaging capacity, 
unwanted immune response, and the availability of lack of efficient large-scale preparation 
impede viral-mediated delivery.89-91  
 
 
Figure 1.3-2 Generic strategy for engineered viral vector mediated delivery of genes. Figure 




1.4 Recombinant RNA Technology 
 General background of recombinant RNA technology 1.4.1
In the past decade, RNA has been transformed into new powerful therapeutic agents in 
pharmaceutical sciences. Many RNAi-based tools have demonstrated promising efficacy in vitro 
and in vivo, and so far over 20 potential RNA therapeutic candidates have made into clinical 
studies. In order to optimize sequence and RNA structure design, improve RNAi target 
prediction, and enhance cellular delivery of RNAi therapeutics, scalable production of large 
quantities of RNA is necessary for further pharmacological testing and investigation. To date, 
RNA has mostly been prepared using either in vitro RNA transcription 93 or solid-phase 
synthesis.94 However, both enzymatic and chemically synthesized RNAs are not capable of 
providing a large quantity of RNA. Using bacteria to produce and accumulate high levels of 
naturally stable recombinant RNA in the cytoplasm might become a cost-effective strategy.21,95 
In vivo RNA expression has been extensively studied using viral infection and promoter to 
produce heterologous messenger RNA (mRNA) in bacteria.34,96,97 Unfortunately, this 
recombinant RNA approach has been plagued by several limitations. For example, heterologous 
transcripts are subject to spontaneous degradation and cleavage due to innate instability and 
ribonucleases (RNAse) in cellular environments.  
 
 New approaches for recombinant RNA technology 1.4.2
Non-coding RNAs, including rRNA and tRNA are considered stable RNA molecules in cells. 
Stable RNA molecules are generally able to form secondary and tertiary structures by either 
RNA folding or RNA-protein assemblies. Stable RNAs show longer half-lives and are protected 
against cellular nucleases under normal growth conditions, compared to mRNAs.98 Until 
 18 
recently, relatively few research groups have adopted stable RNAs as part of their strategy in 
recombinant RNA synthesis. Different RNA scaffold systems have been invented to produce 
stable recombinant RNA in E. coli and overcome obstacles as mentioned above, for instance as 
rRNA variants 99,100 and transfer RNA (tRNA).43,101-103 5S rRNA and tRNA scaffold are two of 
the most successful recombinant RNA expression that can produce and purify target RNA 
molecules from a fermentation-based system. 
 
 
 5S rRNA scaffold 1.4.3
The 5S rRNA structure derived from the marine bacterium, Vibrio proteolyticus and its variants 
have been extensively studied and characterized by Fox group.99,104,105 In previous studies, they 
have identified and created a plasmid-borne mutant of V. proteolytocus 5S rRNA that can be 
produced and accumulated in high levels in cells without being incorporated into E. coli 70S 
ribosomes (Figure 1.4-1).106 Thus, 5S rRNA chimera is an ideal RNA molecule to serve as a 
RNA carrier, to stabilize RNA insert in cellular conditions without any unanticipated side 
effects.107 By using the plasmid-encoded artificial 5S rRNA scaffold, various RNA sequences, 
especially those less than 100 nucleotides, can be expressed and purified without loss of 
functionality from E. coli.106,108-110 Moreover, Fox et al, have described a method for excision of 
RNA insert from 5S rRNA scaffold using biotinylated DNAzyme. The excised RNA products 
were then recovered through DNA-RNA hybridization.109  
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Figure 1.4-1 Sequence and predicted secondary structure of  (a) the V. proteolyticus 5S 
rRNA and (b) the 88-base Bst 5S rRNA scaffold. The RNA of interest could be inserted into 
the Bst site at the DNA level. Bst recognition sites are highlighted with red letters. Figure 
adapted from Pitulle et al106 and Liu et al.109  
 
 tRNA scaffold 1.4.4
Cellular tRNA is subjected to a series of post-transcriptional modifications to avoid RNA 
degradation in cells.111 The advantage of using tRNA as an alternative scaffold is that tRNA 
serves as a protective scaffold that is resistant to nucleases. Thus, recombinant tRNA can 
masquerade as a natural tRNA, and allow RNA insert within the tRNA to fold into native 
confirmation in the cellular environment. The tRNA scaffold approach exploits both human and 
E. coli tRNA to accommodate the insert RNA sequence and produce tRNA fusions. Various 
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RNA sequences have been successfully incorporated in the tRNA scaffold and been produced in 
E. coli.102,103 By incorporating ribozymes and affinity aptamer within the tRNA scaffold, the 
insert RNA can be easily isolated by standard chromatography and denaturing PAGE.95  
 
Figure 1.4-2 Schematic structure of  (a) unmodified human tRNALys, 3 and  (b) tRNA-HBV 
chimera with the epsilon sequence from human HBV virus (boxed). RNA insertion sites are 















1.5 Aims and Organization of the Dissertation 
This project focuses on production, packaging, protection and delivery of functional RNA 
molecules using Qβ VLP. To understand parameters affecting the non-viral RNA packaging 
within VLPs in vivo, structural differences and aptamer affinity of RNA have been thoroughly 
probed by co-expression and co-assembly with Qβ coat proteins in bacteria. Also, the stability of 
packaged RNA from a series of chemical assaults was investigated (Chapter 2).  
 
To develop a single-step, in vivo method for production of functional RNAs packaged within Qβ 
VLPs, a general utility RNAi scaffold has been designed. Cellular uptake of VLPs was assessed 
with various cancer cell lines. The RNAi activities of functional VLPs against different target 
genes were demonstrated. (Chapter 3) 
 
We have initiated the development of compatible cationic polymers for Qβ VLPs to deliver 
plasmid DNA with RNA-filled VLP simultaneously by electrostatic interactions. Particle size 
and surface potential of polymer-conjugated VLP were studied. The feasibility of using polymer-











22. RNA: PACKAGED AND PROTECTED BY VLPS 
 
2.1 Introduction & Motivation 
RNA-based tools have utility in fundamental research, drug discovery, and disease treatment 
49,112,113 in part because of the programmable specificity inherent in base-pairing interactions. 
Small interfering RNAs (siRNAs) and microRNAs (miRNAs) can modulate gene expression by 
directly inhibiting translation or by stimulating degradation of mRNA.114,115 RNAi’s can be 
active as antibacterial or antiviral agents.116,117  
 
Virus Like Particles (VLPs) are devices that can package, protect and deliver RNA. Qβ/MS2 
VLPs are a hollow non-replicative icosahedral nanoparticles with diameters of 30 nm, formed of 
180 copies of the Coat Protein (CP).118,119 Qβ and MS2 are T = 3 icosahedral positive-sense 
single-strand RNA bacteriophages with a small mRNA genomes that encode four open reading 
frames.120 We hypothesize that an optimization of both packaging and protection of RNA within 
these particles has taken place over billions of years of evolution.  
 
Here, focusing on Qβ, explore factors that influence the purity and amount of target RNA that is 
packaged in vivo. We show that intrinsic compaction of RNA increases the efficiency of 
assembly. Intrinsically compact RNA, here derived from rRNA, appears to package with high 
efficiency in vivo. We also characterize the stability of RNA within VLPs and report that VLPs 
chemically protect RNA from metals that can readily penetrate the VLP. VLPs chemically 
stabilize packaged RNA by mechanisms beyond direct exclusion of reactive species from 
proximity to the RNA. 
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2.2 Materials & Methods 
 Reagents 2.2.1
DNA oligos were ordered from Eurofins MWG Operon, Inc. NZY broth media was purchased 
from TEKNOVA. Sec-Butanol and Chloroform and Magnesium Chloride hexahydrate were 
purchased from Fisher Scientific. Ferrous Ammonium Sulfate Hexahydrate was obtained from 
EM Science. Ammonium sulfate was purchased from ICN Biomedicals. Sucrose, RNase- and 
DNase-free, were purchased from Amresco. Dithiothreitol (DTT) was purchased from Research 
Products International Corp. Polyethylene glycol 8000 was purchased from J. T. Baker. (+)-
sodium L-ascorbate was purchased from Sigma-Aldrich. Sodium dodecyl sulfate was purchased 
from Shelton Scientific, Inc. 30% hydrogen peroxide was purchased from Fisher Scientific. BCA 
protein assay kit was purchased from Thermo Scientific. Low range ssRNA ladder was 
purchased from New England Biolabs. Ultra-Pure SequGel was purchased from National 
Diagnostics. Polyallomer centrifuge tubes were purchased from Beckman Coulter. Agilent RNA 
6000 Nano Kit was purchased from Agilent Technologies. Amicon® Ultra centrifugal filters 
(100 kDa MWCO) were purchased from Millipore. Spectra/Por® dialysis tubing (15 KDa 
MWCO) was purchased from Spectrum® Laboratories, Inc. All other reagents were analytical 
grade. All DNA constructs were confirmed by sequence analysis (Eurofins MWG Operon).  
 
 Construction of Qβ CP and Qβ VLP-RNA expression vector 2.2.2
In this study, we used a two-plasmid expression system for the production of Qβ VLP and non-
viral RNA in E. coli. Thus, two compatible origins of replication and antibiotic resistance 
markers are required within the same host strain. The pBR322 origin of replication and 
kanamycin resistance gene of pET-28b (+) is compatible with the CloDF13 origin and 
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streptomycin resistance gene in pCDF-1b, allowing for co-transformation in the same bacterial 
cell. Therefore, we chose pCDF-1b as a coat protein expression vector (pCDF-CP) (Figure 2.3-
1a,c) and pET-28b (+) as an RNA expression vector (pET-RNA) (Figure 2.3-1b). The non-viral 
RNAs and Qβ CP were cloned downstream of the T7 promoter/lac operator.  
 
 Qβ coat protein expression vector  2.2.3
DNA encoding Qβ CP monomer (NCBI reference sequence: NC_001890.1) was synthesized by 
recursive-PCR (R-PCR)121 with restriction sites Nco I and Avr II (Table 5.1-1) and cloned into 
pCDF-1b (Novagen) to generate plasmid pCDF-CP. E. coli BL21(DE3) transformants were 
selected based on LB streptomycin resistance (50µg mL-1) and screened for inserts by colony 
PCR. All constructs were sequence confirmed (MWG Operon). 
 
 RNA expression vector 2.2.4
a-rRNA 122 and Thermus thermophiles 23S rRNA (NCBI reference sequence: 3169129)  were 
chosen as highly structural RNA. GFP mRNA derived from gWizGFP (Genlantis) was chosen as 
non-structural RNA. Template DNAs, including the corresponding Qβ hp, spacer region, and 
RBS were synthesized by R-PCR 121. The template DNAs (Table 5.2-2) flanked by XbaI and 
BlpI were then cloned into pET28-b (+) (Novagen) to generate the Qβ VLP-RNA expression 
vectors. E. coli BL21(DE3) pCDF-CP/pET28-b (+)-VLP-RNA transformants were selected 
based on LB streptomycin/kanamycin resistance (50µg mL-1). The insert sequence was further 




 Expression of Qβ VLP and VLP-RNA complexes 2.2.5
E. coli containing pCDF-Qβ CP vector was inoculated in NZY medium with streptomycin (50µg 
mL-1) and incubated overnight at 37°C. Qβ-VLP production started with the addition of 1% 
overnight culture to the ZYM-5052 auto-induction medium 123. Production culture was incubated 
24 h at 37°C. Cells were collected by centrifugation at 4°C and 6500xg for 30 minnutes. Cells 
were resuspended in equal volume of Qβ buffer (10 mM MgCl2 and 20 mM Tris-HCl, pH7.5) 
and lysed by sonication at 40 watts for three minutes with 10s on/off intervals. The lysate was 
centrifuged to remove cell debris for 30 minutes at 23,430xg. 2M Ammonium sulfate 
precipitation followed by 30-minute centrifugation at 23,430xg was performed to obtain crude 
VLP. Crude VLPs were then suspended in 1 mL Qβ buffer and extracted with 1:1 n-
butanol:chloroform. Organic extraction was repeated three times. The aqueous layer was 
subsequently purified by step sucrose gradient ultracentrifugation (10-40% w:v) in a SW41Ti 
rotor (Beckman) at 40K RPM for two hours. Qβ VLPs were precipitated from the sucrose 
fraction with 20% w:v PEG8000. Resuspended Qβ VLPs were combined and dialyzed against 2 
L dialysis buffer (20 mM Tris-HCl, pH 7.5 and 50 mM NaCl) for two hours. This procedure was 
repeated three times prior to the use of particles in further analyses. Qβ VLPs were characterized 
by SDS polyacrylamide gel electrophoresis. VLP-RNA complexes were obtained as described 
above using co-expression strategy in E. coli BL21 (DE3) pCDF-CP/pET28-b(+)-GFP strain 
selected with streptomycin/kanamycin (50µg mL-1).  
 
 Recombinant RNA extraction from Qβ VLPs 2.2.6
VLPs and VLP-RNA complexes were expressed and purified as described above. An amount of 
50 µg VLP was added to 250 µL of the extraction buffer (5% SDS, 25 mM DTT, 20mM Tris-
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HCl, pH 7.5, and 50 mM NaCl). The solution was incubated at room temperature for 20 minutes. 
Equal volume of low pH phenol-chloroform was then added to the solution. The RNA extracts 
were centrifuged to remove protein and DNA for 15 minutes at 16,300xg. RNA retained in 
aqueous phase was precipitated. Ammonium acetate precipitation was performed at -20 °C for at 
least 24 h followed by 15-minute centrifugation at 16,300xg. The RNA pellet was washed with 
80% ethanol at least three times to remove excess salt. The RNA was dissolved in nuclease free 
water and stored at -80 °C. Using this extraction method, RNA yield was about 4-5 µg for every 
50 µg VLP or VLP-RNA complexes. RNA samples were analyzed by denaturing urea 
polyacrylamide gel electrophoresis or Agilent 2100 Bioanalyzer.  
 
 Transmission electron microscopy 2.2.7
All TEM images were obtained using a Hitachi H-7500 electron microscope. Samples were 
prepared by fixing with 250 µL of glutaraldehyde (8%) per 500 µL of sample (1µg/mL). A drop 
of the sample, ~15 µL, was dropped on the copper grid and incubated for five minutes. Excess 
sample was wicked off the grid using filter paper. The grid was then placed face down on a drop 
of 2% ammonium molybdate stain for two minutes. Excess stain was wicked off using filter 
paper and the grid was dried for two hours before imaging.  
 
 Hydroxyl radical cleavage generated from Fenton reaction 2.2.8
This method was adopted from hydroxyl radical footprinting methodology 124 with slightly 
modifications. For various time points in uniform amounts of hydroxyl radical generated from 
the Fenton reaction, VLP-RNA complexes (250 µg) or packaged RNA alone (25 µg) was added 
to pre-cleavage solution (0.3% H2O2, 3.3 mM sodium ascorbate, 20 mM Tris-HCl, pH 7.4) to 50 
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µL. The hydroxyl radical cleavage initiates when 10 µL of freshly prepared 200 µM iron (II) 
EDTA solution was introduced. For mixture of iron (II) EDTA solution, the ratio of  
(NH4)2Fe(SO4)26H2O to EDTA solution is 2:1 (e.g. 200 µM (NH4)2Fe(SO4)26H2O/ 400 µM 
EDTA ). The cleavage reaction was then quenched after various times (0-180 minutes) by 
treating 20 µL of 0.1 M thiourea.  In varying concentrations of hydroxyl radical incubated for 
uniform time increments, 10 µL of different concentrations of iron (II) EDTA solution (0-1500 
µM) were prepared and added to individual pre-cleavage solution with VLP-RNA complexes 
(250 µg) or packaged RNA alone (25 µg). The cleavage reactions were terminated after 15 
minutes by addition of 20 µL of 0.1 M thiourea. RNA extraction was performed according to the 
procedures mentioned above. 
 
 Inline cleavage induced by magnesium ions 2.2.9
The methodology originated from the previous work on the inline probing analysis of 
riboswitches 125. For different incubation periods at a constant magnesium ion concentration that 
promote inline cleavage, VLP-RNA complexes (250 µg) or packaged RNA alone (25 µg) was 
added to Mg cleavage solution (25 mM MgCl26H2O, 20 mM Tris-HCl, pH 7.4) to 60 µL. 
Samples were incubated at 37 °C for different time periods (0-120 hours). In varying 
concentrations of Mg2+ ions at constant periods of time, VLP-RNA complexes (250 µg) or 
packaged RNA alone (25 µg) was added to Mg cleavage solution with elevated concentrations of 
MgCl2 (0-300 mM). All samples were incubated at 37 °C for 15 minutes. The inline cleavage 
reactions were paused by storing at -80°C. RNA extractions from the different incubation 
periods or different Mg2+ ions concentrations were performed according to the procedures 
mentioned above.   
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 Slow unmediated cleavage 2.2.10
 
VLP-RNA complexes (250 µg) or packaged RNA alone (25 µg) was added to unmediated 
cleavage solution (20 mM Tris-HCl, pH 7.4) to a final volume of 60 µL. All samples were 
incubated at room temperature for different time periods. The slow unmediated cleavage 
reactions were halted by storing at -80°C.  RNA extractions from the different incubation periods 
were performed according to the procedures mentioned above. 
 
 RNA integrity analysis 2.2.11
The packaged a-rRNA-hp samples were run on a denaturing urea polyacrylamide gel with 
SYBR® Green II RNA gel stain and quantitated with AlphaView® software. The integrated pixel 
intensity for the area under major RNA band was used to represent a-rRNA-hp band intensity. 
Here, the band intensity representing the % uncleaved a-rRNA-hp by various conditions was 
normalized to control a-rRNA-hp samples. The values of % uncleaved a-rRNA-hp were 
calculated by dividing the remaining a-rRNA-hp band intensity by the control a-rRNA-hp band 









 Design of RNAs for studying VLP packaging efficiency 2.3.1
A series of RNAs were constructed here to determine the effects of various RNA properties and 
sequences, separately and in combination, on the efficiency of VLP packaging. The series of 
RNAs allows us to investigate effects of RNA size, structure and degree of intrinsic compaction, 
effects of competition with binding to the ribosome, and the effect of Qβ hp on the amount of 
target RNA and amount of contaminating RNA packaged into VLPs in vivo.  
 
To investigate VLP packaging of a highly structured and compacted RNA, and to determine the 
effect of the Qβ hp on packing of such RNAs, VLPs containing a-rRNA 126 with and without the 
Qβ hp were characterized. a-RNA is a well-characterized RNA derived from the core of the 
Thermus thermophilus large ribosomal subunit rRNA.  
 
To determine the effect of RNA size, a large RNA, the intact T. thermophilus 23S rRNA was 
also fused to the Qβ hp (Figure 2.3-1d-e). To characterize the effect of competition from 
ribosomal binding, the RNA ribosomal binding site RBS, 127 was fused to a-rRNA Qβ-hp. To 
characterize packaging of a flexible and extended RNA, an mRNA (encoding green fluorescent 
protein (GFP)) was fused to the Qβ hp (Figure 2.3-1g). To further characterize the effect of 
competing RNA binding factors, the RBS was added upstream of the mRNAGFP Qβ-hp (Figure 
2.3-1f). Throughout this series of experiments coat protein was expressed in pCDF-1b (pCDF-





Figure 2.3-1 The protein expression vector (pCDF-CP), RNA production vector (pET-
RNA), and the series of RNA constructs used in this study. (a-b) The pCDF-CP and pET-
RNA plasmids used to co-express protein and RNA in E. coli. The red line on pET-RNA 
plasmid (b) indicates the RNA transcript. Genes that encode the desired protein or RNA 
product for co-expression are (c) Qβ coat protein, (d) a-rRNA-hp, (e) 23S rRNA-hp, (f) 
RBS-mRNAGFP-hp, (g) mRNAGFP-hp, and (h) a-rRNA. 
 
 Packaging of short and long RNAs 2.3.2
CP and various target RNAs were co-expressed, and the resulting VLPs were purified. SDS-
PAGE analysis and transmission electron microscopy (Figure 2.3-2a-b) confirmed co-expression 
of CP and RNA leads to formation of canonical VLPs that contain the target RNA. Amount of 
target RNA incorporated into the VLP was quantitated and normalized to amount of CP mRNA. 
The results show that RNAs of up to 3,051 nucleotides can be efficiently packaged in Qb VLPs. 
The a-rRNA-hp (747 nucleotides) is efficiently packaged within VLPs (Figure 2.3-2c). The 23S 
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rRNA-hp (3,051 nucleotides), which is four times larger than a-rRNA-hp, is packaged within 
VLPs with similar efficiency (Figure 2.3-2d). Both of these VLPs contain a small amount of 
contaminating mRNA encoding Qβ CP, as observed previously.36  
 
We used amount of packaged CP mRNA as a reference to estimate packaging efficiency of other 
RNAs. RNAs that packaged in great excess of CP mRNA are considered to be efficiently 
packaged. RNAs that are incorporated to levels equivalent to CP mRNA are considered to be 
inefficiently packaged.  Packaged RNA impurities of molecular weight less than than 23S rRNA-
hp are observed. These species may be 23S rRNA degradation products or endogenous E. coli 
sourced impurities, which are also observed with a-RNA-hp VLPs. 
 
 Packaging of RNAs with varying structure and compaction 2.3.3
Intrinsic RNA structure appears to play a significant role in packaging efficiency within VLPs in 
E. coli. It has been shown that a-rRNA 126 and 23S rRNA 128 fold to compact secondary and 
tertiary structures in the presence of magnesium. We compared VLP packaging of a-rRNA-hp to 
mRNAGFP-hp. The lengths of mRNAGFP-hp and a-rRNA-hp are similar, and both contain the Qβ 
hairpin. However, mRNAGFP-hp differs from a-rRNA-hp in that mRNAs are less structured, less 
compact and more dynamic than rRNAs. The results show that a-rRNA-hp is packaged more 
efficiently than mRNAGFP-hp (Figure 2.3-1d,f, Figure 2.3-3a), suggesting that in general highly 
structured RNAs are packaged more efficiently than non-structured RNAs. 
 
 Packaging of RNAs is influenced by competing RNA binding factors 2.3.4
We determined whether ribosomes can compete with VLP assembly by binding to target RNA. 
Comparing mRNAGFP-hp bearing an RBS (figure 2.3-1f) with mRNAGFP-hp lacking an RBS 
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(figure 2.3-1g) shows that RNA packaging efficiency in VLPs decreases slightly when the RNA 
contains an RBS (Figure 2.3-3a). This result suggests competition between ribosomal binding 
and Qβ assembly in vivo.  
 
 Packaging of RNAs required the Qβ hairpin 2.3.5
The Qβ hp is necessary for efficient packaging of essentially any RNA within a Qβ VLP. a-
rRNA fused to the Qβ hp shows the highest packaging efficiency of any RNA tested here. We 
investigated the importance of the Qβ hp to packaging of a highly structured RNA by removing 
Qβ hp from a-rRNA (Figure 2.3-1h). Removal of the Qβ hp essentially abolishes packaging of a-
RNA (Figure 2.3-3b). These results indicate that efficient packaging of RNA within the VLPs in 












Figure 2.3-2 in vivo expressed RNA is packaged within VLPs to form VLP-RNA 
assemblies. (a) Purified Qβ -VLPs were analyzed by SDS-PAGE. The Qβ CP monomer is 
14.5 kDa. Lane 1: Protein Sizing Ladder. Lane 2: Qβ CP monomer from purified Qβ -
VLPs. (b) Transmission electron microscope images of Qβ -VLP containing a-rRNA-hp. 
Scale bar= 50 nm. (c) in vivo expressed a-rRNA-hp, extracted from purified Qβ –VLPs, 
subjected to electrophoresis on denaturing Urea PAGE. Lane 1: RNA ladder, Lane 2: 
RNAs of Qβ CP expressed alone. Lane 3: RNAs of purified Qβ CP co-expressed with a-
rRNA-hp. The arrow indicates the a-rRNA-hp (747 nt). (d) in vivo expressed 23S rRNA-hp, 
extracted from purified Qβ –VLP, subjected to microfluidic-based chip electrophoresis. 
Lane 1: RNA sizing ladder, Lane 2: RNAs extracted from purified Qβ CP co-expressed 

























Figure 2.3-3 Highly structured RNA and a high affinity RNA aptamer are two critical 
elements for efficient in vivo non-viral RNA packaging. (a) structured and unstructured 
RNAs, packaged in vivo by Qβ CP. Lane 1: RNA Ladder. Lane 2: RNAs extracted from 
purified Qβ CP co-expressed with RBS-mRNAGFP-hp. Lane 3: RNAs from purified Qβ 
CP co-expressed with mRNAGFP-hp. Lane 4: RNAs from purified Qβ CP co-expressed 
with a-rRNA-hp. (b) RNAs with and without the Qβ hp, co-expressed in vivo with Qβ CP. 
Lane 1: RNA Ladder. Lane 2: RNAs of purified Qβ CP co-expressed with a-rRNA-hp. 
Lane 3: RNAs of purified Qβ CP co-expressed with a-rRNA (without Qβ hp). Lane 4: 
RNAs of Qβ CP expressed alone. One hundred nanograms of total VLP-extracted RNA 
was loaded to each well for denaturing PAGE. Band A: RBS-mRNAGFP-hp (851 nt). Band 
B: mRNAGFP-hp (833 nt, without the RBS). Band C: a-rRNA-hp (747 nt). Band D: Qβ CP 
mRNA. 
 VLPs protect RNA from Fenton chemistry 2.3.6
VLPs have previously been shown to protect RNA from nucleases.129 Here, we investigated the 
ability of Qβ VLPs to protect packaged RNA from chemical assault. We compared the rates of 
degradation of a-rRNA-hp, which packages efficiently, when it is packaged in VLPs or free in 
 36 
solution. The percent of uncleaved RNA was determined after RNA extraction and separation on 
urea gel.  
 
Qβ VLPs protect RNAs against attack by hydroxyl radical. After incubation in Fe-EDTA, O2 and 
H2O2, conditions known to generate hydroxyl radical,130 a-rRNA-hp packaged within VLPs 
remains about 60% intact after three hours. In contrast, only 30% of the same RNA, unprotected 
by VLPs (free a-rRNA-hp), remains intact under the same conditions (Figure 2.3-4a). The 
relative extent of protection increases with time. Similarly, protection of a-rRNA-hp within 
VLPs can be observed in a series of experiments in which Fe-EDTA concentration is varied at 
fixed time. After 15 minutes in 1500 µM Fe-EDTA and H2O2, about 80% of VLP-packaged 
RNA remains intact, while less than 50% of free RNA remains (Figure 2.3-4b).  
 
 VLPs protect RNA from in-line cleavage 2.3.7
VLPs protect a-rRNA-hp against magnesium-mediated in-line cleavage. In-line cleavage is 
intramolecular attack by the nucleophilic  2’ hydroxyl on the proximal phosphate. Magnesium is 
known to catalyze in-line cleavage of RNA.131,132 After 36 hours of incubation in 25 mM MgCl2 
at 37°C, the RNA within VLPs is about 90% intact. By contrast, only 5% of free a-rRNA-hp is 
intact under the same conditions (Figure 2.3-4c). Similarly, VLP packaging increases the 
concentration of MgCl2 required to cleave RNA over specific periods of time. About 35% of 
VLP-packaged a-rRNA-hp remains intact after 24 hours at an MgCl2 concentration of 100 mM. 
There is no detectable free RNA remaining after the same incubation time under the same 
cleavage conditions (Figure 2.3-4d). 
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 VLPs cannot protect RNA from slow unmediated cleavage 2.3.8
Here we assayed rates of unmediated cleavage of VLP-packaged RNA in comparison to free 
RNA. RNA in the presence of buffer and monovalent cations degrades slowly at room 
temperature. Rates of unmediated cleavage are an order of magnitude less than rates by 
magnesium-mediated in-line cleavage or Fenton cleavage. Our results show that both VLP-
packaged and free a-rRNA-hp slowly degrade at 37°C in the absence of Mg2+. There is no 
significant difference between rates of degradation of VLP-packaged RNA and free RNA. The 
VLP does not appear to retard the rate of unmediated RNA degradation over extended periods of 





Figure 2.3-4 VLP packaging confers chemical stability to RNA. VLP-packaged a-rRNA-hp 
and free a-rRNA-hp were incubated (a) for various time in 200 µM Fe-EDTA and 1% 
H2O2 in the presence of atmospheric oxygen at 37°C, which promotes Fenton cleavage (b) 
in varying [Fe-EDTA], incubated for 15 minutes at 37°C, (c) for variable time in 25 mM 
MgCl2 at 37°C, which promotes in-line cleavage, (d) in varying [Mg2+] for 24 hours at 
37°C, and (e) for variable time at neutral pH in the absence of divalent cations. For all 
experiments here, the uncleaved a-rRNA-hp was isolated by denaturing urea PAGE and 
quantitated with AlphaView® software for FluorChem systems. 
 
2.4 Discussion 
Potency and efficacy of VLPs that act via delivery of functional RNAs are related to initial 
functionality, purity and quantity of the packaged RNA and to the chemical stability of the RNA 
within the VLP. Using E. coli for combined expression and packaging of RNA into Qβ VLPs, 
we probed relationships between packaging efficiency and RNA size, sequence and intrinsic 
compaction. We characterized the degree of RNA protection conferred by VLPs from small 
diffusible agents such as hydroxyl radical and magnesium cations. The results indicate that in 
vivo RNA packaging of RNA within VLPs is most efficient for intrinsically compact RNAs such 
as rRNA and is less efficient for dynamic, elongated RNAs such as mRNAs. The Qβ hp is 
necessary but not sufficient for efficient packaging. Qβ VLPs protect RNA not only against 
nucleases 133 but against assault by small diffusible species.  
 
Stockley previously suggested that for viral RNA, stem-loops dispersed through the MS2 viral 
genome interact with CP during assembly 134-136 and tentatively identified 60 RNA stem-loops in 
the MS2 genome.40 Initial RNA collapse during assembly in vitro depends initially on RNA-
protein interactions, followed by CP-CP interactions.137 Packaging involves multiple weak RNA-
CP interactions along the length of the viral RNA and a single strong interaction with the MS2 
hp.39 MS2 and Qβ CP share about 25% amino acid sequence identity,138-140 with highly similar 
three-dimensional structures and RNA binding sites.  
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We conclude that in vivo packaging efficiency of non-viral RNA within Qβ VLPs is high when 
the RNA (i) is intrinsically compact, (ii) includes the Qβ hp, (iii) lacks binding sites for 
assemblies that compete with CP (e.g., the RBS), and (vi) is as large as the 23S rRNA (2,970 nt). 
We prepared a series of RNAs (Figure 1) and co-expressed the RNA with Qβ CP in E. coli. The 
expressed RNAs contain i) a-rRNA, a ~650 nt intrinsically compact RNA stabilized by 11 
GNRA tetraloops,126 ii) 23S rRNA, a ~2,970 nt intrinsically compact RNA containing over forty 
stem-loops, and iii) mRNAGFP, an unstructured ~780 nt RNA. The expressed RNAs either 
incorporated or lacked the Qβ hp, and/or an RBS. The results show that both a-rRNA-hp and 23S 
rRNA-hp are efficiently packaged within Qβ VLP in vivo (Figure 2.3-2), suggesting that within 
the limits explored here RNA length is not a strong predictor of packaging efficiency. We 
compared the packaging efficiency of intrinsically compact a-rRNA-hp and unstructured 
mRNAGFP-hp. The results of these experiments show higher packaging of intrinsically 
compacted rRNA than unstructured mRNA (Figure 2.3-3a).  We conclude that intrinsic RNA 
compaction has significant influence on the efficiency of in vivo RNA packaging in Qβ VLPs.  
 
The Qβ hp is necessary but not sufficient for efficient packaging of RNA into VLPs within E. 
coli (Figure 2.3-3b). This finding is consistent with previous work showing that RNAs lacking 
the MS2 hairpin do not interact with MS2 CP in vitro.137 The MS2 hairpin is thought to be the 
initiation trigger for viral capsid formation.141-144 Our results confirm that numerous GNRA 
tetraloops, as found on the surface of a-rRNA, do not substitute for the Qβ hp during RNA 
packaging in vivo.  
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Finn and coworkers found VLP packaging of CP mRNA competes with CP expression. When 
the Qβ hp is fused the 3’ end of the CP mRNA, expression of Qβ CP decreases.2 Our results, 
showing that RBS decreases mRNAGFP–hp packaging in the VLP, confirm that Qβ CP and the 
ribosome compete binding to mRNAGFP–hp. RNA packaging efficiency in VLPs is slightly 
decreased when an RBS is introduced upstream of the mRNAGFP-hp (Figure 2.3-3a). Based on 
previous studies and our current findings, we expect that introduction of additional high-affinity 
RNA binding sites on RNA to be packaged in vivo could facilitate or attenuate RNA packaging 
efficiency consistent with the inherent affinity for the RNA.  
 
We and others observe that non-target RNAs, including Qb CP mRNA. tRNAs, etc., are 
packaged within VLPs along with target RNA. Contaminating RNAs compete with target RNA 
during co-assembly. The absolute amount of contaminating RNA depends of the extent of 
packaging of the target RNA. If target RNA is expressed at low levels, or lacks the Qb hp, then 
the amount of contaminating RNA is increased. In total, it appears that sufficient RNA is 
packaged in the VLP to fully compensate for the cationic charge of Qb CP.145 It is possible that 
RNA is required within the VLP for charge neutralization of positive charge 146. In our two-
plasmid expression system, T7 RNA polymerase was used to induce high-level expression of 
both Qβ CP and target RNAs. Without the simultaneous expression of RNA in vivo, high 
concentrations of positively charged viral CP may form non-specific RNA-CP interactions that 
serve to stabilize the protein structure and neutralize RNA charge.147 
 
RNAs packaged within MS2 VLPs are completely protected from digestion from plasma 
ribonucleases.129 The mechanism of this protection is steric; the enzymes are significantly larger 
 42 
than the pores in the VLP capsid. Here we determine whether VLPs protect RNA against small 
diffusible damaging agents. 
 
We determine the level of protection afforded by Qβ VLP against strand cleavage by metal ions. 
Mechanisms and levels of protection against small reactive molecules such as metal ions are 
expected to be distinctive from those of nucleases because Qβ VLPs contain holes 119 that are 
significantly larger than the metal ions and their hydrates. Pores in VLPs allow entry and exit of 
metal ions and species such as hydroxyl radical. Diffusion of metal ions into Qβ VLPs has been 
demonstrated by Finn, who showed that RNA packaged in VLPs is degraded by lead(II) 
acetate.148 It has been shown that RNA within MS2 VLPs is degraded by high pH.12  
 
Our results demonstrate as expected that Mg2+ and Fe2+ enter VLPs and degrade RNA. The 
results are consistent with expectations that rates of RNA cleavage in the interior of VLPs caused 
these metals are highly attenuated compared to rates of cleavage of free RNA in solution. RNA 
is substantially protected by VLPs against hydroxyl radical and magnesium-mediated in-line 
cleavage (Figure 2.3-4). It is known that rates of hydroxyl radical 149 and magnesium-mediated 
in-line cleavage 131 of RNA are influenced by RNA compaction and dynamics. RNA is more 
compact and less dynamic within VLPs than RNA that is free in solution.150  
 
The RNA backbone is cleaved spontaneously in the presence and absence of magnesium.131,132 
The mechanism is thought to be the same for both reactions; intramolecular in-line cleavage with 
a linear arrangement of the nucleophile (the 2’ oxygen), the electrophile (the P) and the leaving 
group (the 5’ oxygen). The reaction is faster in the presence of magnesium because it stabilizes 
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the transition state by accepting a proton from the 2’oxygen and/or by withdrawing electon 
density from the phosphorous. Flexible regions of RNA are most labile to in-line cleavage 
because they more frequently occupy transient conformational states similar to in the transition 
state.131,132 As expected, in the presence of magnesium the rate of cleavage decreases when RNA 
is packaged in the VLP. The reaction rate decreases because dynamics of RNA within the VLP 




































33. FUNCTIONAL RNAS: COMBINED ASSEMBLY AND PACKAGING IN 
VLPS 
 
3.1 Introduction & Motivation 
In chapter 2, we probed relationships between packaging efficiency and RNA size, sequence 
and intrinsic compaction. We also investigated the extent of chemical protection conferred by 
VLPs on RNA. These finding may allow us to further develop potential RNAi platform. In this 
chapter, we describe combined co-expression and assembly of a designed RNA molecule and its 
protective particle in E. coli. The particles are stable and readily absorbed by cells, where RNAs 
are released and processed to functional states. The RNA production, packaging and delivery 
system described here is based on bacteriophage Qβ. A high affinity CP binding site on Qβ 
genomic RNA has been isolated as a 29-nucleotide RNA hairpin, known as the Qβ hairpin.37,38 
CP and target RNA can be co-expressed in E. coli to spontaneously form VLPs.36,37 The Qβ CP 
can encapsulate molecular cargo during in vitro or in vivo assembly.137,151,152 Qβ VLPs are robust, 
retaining and protecting enzymes that remain catalytically active over broad ranges of 
temperatures.151 They contain pores,153 by which small substrate and product molecules can enter 
and exit.151 Qβ VLPs lack components of the phage genome and are replication-incompetent.154  
 
Functional RNAs such as small interfering RNA (siRNA), microRNA (miRNA), and short 
hairpin RNA (shRNA) have utility in therapeutic 155 and research applications.156,157 Increased 
adoption of RNA-based therapeutics would be assisted by improved production and delivery 
processes, some of which currently employ small molecules, polymers, lipids, peptides, aptamers 
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and proteins.75 Here we demonstrate a single-step in vivo method for production and packaging 
of functional RNA molecules in Qβ VLPs. The method employs our designed RNAi scaffold 
that folds by intramolecular processes. The assembly occurs within E. coli and produces VLP-
RNAi particles. The RNAi scaffold (Figure 3.1-1) is a general utility chimera that contains a 
functional sequence paired to a carrier sequence combined with stability, packaging and 
processing elements. The scaffold contains the Qβ hairpin 37,38 on the 5’ end to confer affinity for 
the CP, and a miR-30 stem-loop 158,159 that is demonstrated to be of utility for inhibition of gene 
expression.158,160 With our scaffold, functional duplex RNAs form by an intramolecular process,  
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Figure 3.1-1 The Qβ RNAi scaffold is designed to fold and assemble with CP in vivo. A 
single RNA molecule folds to form a Qβ hairpin (blue) linked to a miR-30B stem loop 
(green), which caps the functional RNA duplex (yellow/red). The functional RNA duplex 
can encode miRNA or siRNA. The scaffold can incorporate any 22 base pair sequence, 
depending on the desired target. (a) An RNAi scaffold that targets GFP mRNA. (b) An 
RNAi scaffold that targets the Pan-ras 3’ UTR. 
 
which is concentration independent and efficient in vivo. The silencing RNA component remains 
in the duplex state 161,162 within the VLP and is therefore functional when delivered to the 
cytoplasm. The RNA is released from the VLP in the cell, were it is expected that dicer protein 
would liberate the functional ~22 nucleotide element from the scaffold.163,164 The functional RNA 
enters the RNA-induced silencing complex (RISC complex) to induce RNA interference.158-160 
 
3.2 Materials & Methods 
 
 Reagents 3.2.1
GFP was purchased from EMD Millipore. DyLight 633 Amine-Reactive kit was purchased from 
Thermo Scientific. DNA oligos were ordered from Eurofins MWG Operon, Inc. NZY broth 
media was purchased from TEKNOVA. Polyallomer centrifuge tubes were purchased from 
Beckman Coulter. Amicon® Ultra centrifugal filters (100 kDa MWCO) were purchased from 
Millipore. Spectra/Por® dialysis tubing (15 KDa MWCO) was purchased from Spectrum® 
Laboratories, Inc. sec-Butanol and Chloroform were purchased from Fisher Scientific. 
Ammonium sulfate was purchased from ICN Biomedicals. Sucrose, RNase- and DNase-free, 
was purchased from Amresco. HeLa cells were obtained from the American Type Culture 
Collection (Manassas, VA, USA), U87 human glioblastoma cells were a gift from Dr. Kuo-Chen 
Wei at the Department of Neurosurgery (Chang Gung Memorial Hospital, Taiwan) and were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 
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bovine serum (FBS). Primary Pan-Ras antibodies were purchased from Santa Cruz 
biotechnology. Secondary antibody, horseradish peroxidase-conjugated goat anti-mouse IgG was 
purchased from PerkinElmer. Glass bottom microwell dishes were purchased from MatTek. XTT 
kit was purchased from Sigma. All other reagents were analytical grade. All DNA constructs 
were confirmed by sequence analysis (Eurofins MWG Operon).  
 
 Construction of Qβ-VLP, VLP-RNAi and GFP-containing VLP expression vectors 3.2.2
Qβ coat protein expression vector. DNA encoding Qβ CP monomer (NCBI reference sequence: 
NC_001890.1) was synthesized by recursive-PCR (R-PCR) 121 with restriction sites Nco I and 
Avr II (Table 5.2-3) and cloned into pCDF-1b (Novagen) to generate plasmid pCDF-CP. E. coli 
BL21(DE3) transformants were selected based on LB streptomycin resistance (50μg mL-1) and 
screened for inserts by colony PCR.  
 
RNAi scaffold expression vector. Human miR-30B pre-miRNA was used as a scaffold for 22 
bases of GFP (GenBank: AB038602.1, 5’-CAA CAT TCT GGG ACA CAA ATT G-3’) or let-7 
(NCBI reference sequence: NR_029660.1, 5’-TGA GGT AGT AGT TTG TAC AGT T-3’) 
RNAi sequences and their complements. Template DNAs, including the T7 promoter and T7 
terminator regions needed for RNA transcription, were synthesized by R-PCR.121 The DNA 
sequences encoding RNAi scaffold containing RNAiGFP or RNAilet-7 (Table 5.2-4) were cloned 
into pET28-b(+) (Novagen) to generate the Qβ VLP-RNAi scaffold expression vectors. E. coli 
BL21(DE3) pCDF-CP/pET28-b(+)-VLP-RNAi transformants were selected based on LB 
streptomycin/kanamycin resistance (50μg mL-1). 
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GFP expression vector. The DNA gene encoding GFP was amplified by PCR from gWizGFP 
(Genlantis) with restriction sites BglII and BlpI (Table 5.2-3) and cloned into pET28-b (+) 
(Novagen) to generate plasmid pET28-b (+)-GFP. E. coli BL21 (DE3) pCDF-CP/ pET28-b (+)-
GFP transformants were selected based on LB streptomycin/kanamycin resistance (50μg mL-1). 
 
 Expression of Qβ VLP and GFP-containing VLP 3.2.3
E. coli containing pCDF-CP vector was inoculated in NZY medium with streptomycin (50μg 
mL-1) and incubated overnight at 37 °C. Expression was induced by 1:100 dilution of overnight 
culture in 500 mL of ZYM-5052 auto-induction medium.123 Production culture was incubated 24 
h at 37 °C. Cells were collected by centrifugation at 4 °C and 6500xg for 30 min. Cells were 
resuspended in an equal volume of Qβ buffer (10 mM MgCl2 and 20 mM Tris-HCl, pH7.5) and 
lysed by sonication at 40 watts for three minutes with 10s on/off intervals. The lysate was 
centrifuged to remove cell debris for 30 minutes at 23,430xg. 2M Ammonium sulfate 
precipitation followed by a 30-minute centrifugation at 23,430xg was used to obtain crude VLPs. 
Crude VLPs were resuspended in 1 mL Qβ buffer and extracted with 1:1 n-butanol:chloroform. 
Organic extraction was repeated three times. The aqueous layer was subsequently purified by 
step sucrose gradient ultracentrifugation (10-40% w:v) in a SW41Ti rotor (Beckman) at 40K 
RPM for two hours. VLPs were precipitated from the sucrose fraction with 20% w:v PEG8000. 
VLPs were resuspended in 25 mL of Qβ buffer, combined, and dialyzed against 2L dialysis 
buffer (20 mM Tris, pH 7.5 and 50 mM NaCl) overnight. This procedure was repeated an extra 
three times for 2 h prior to the use of VLPs in analyses. VLP concentration was assessed by 
Pierce BCA Protein Assay kit. GFP-containing VLP was expressed as described above using E. 
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coli BL21(DE3) pCDF-CP/pET28-b(+)-GFP strain selected with streptomycin/kanamycin (50μg 
mL-1).  
 
 Conjugation of Dylight 633 NHS Ester to Qβ-VLPs pression of Qβ VLP and GFP-3.2.4
containing VLP 
Conjugation of DyLight 633 N-hydroxysuccinimide (NHS) ester to VLPs was performed 
according to manufacturer protocols with slight modifications. VLPs were dialyzed against 0.05 
M sodium borate buffer at pH 8.5 (labeling buffer) to remove the Tris present in Qβ buffer. 
VLPs (100 μL of 1 mg mL-1) were incubated with 200 μL DyLight 633 NHS ester reagent (1 mg 
mL-1) at room temperature for one hour. Buffer exchange was performed to remove non-reacted 
reagent using centrifugal filter unit with a 100 kDa molecular-weight cutoff. DyLight 633-
labeled Qβ-VLPs were stored at -80 °C following GFP in vitro encapsidation. 
 
 In vitro encapsulation of GFP within Qβ-VLPs 3.2.5
VLPs were expressed and purified as described above. DyLight 633-labeled VLPs (10mg/mL) 
were incubated in disassembly buffer (20 mM Tris-HCl, 50 mM NaCl, 6M urea and 10 mM 
dithiothreitol) at 4 °C for one hour to disassemble VLP into CP dimers and posteriorly dialyzed 
against 10 mM acetic acid with 50 mM NaCl. Dialyzed CP dimers were then applied to a 
Sephadex G75 column and concentrated by a centrifugal filter unit (3.5 kDa MWCO). 
Subsequently, DyLight 633 labeled Qβ-VLPs were combined with a five-fold molar excess of 
GFP in dialysis tubing (3.5 kDa MWCO). VLP dimers and GFP were dialyzed against 2L of 
reassembling buffer (20 mM Tris-HCl, pH 7.5, 50 mM NaCl) three times at 4 °C for at least 24 
h. Excess GFP and unassembled dimers were removed by centrifugation (100 kDa MWCO). 
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 Confocal microscopy 3.2.6
HeLa cells (2 x 105 cells) were seeded into glass bottom microwell dishes (MatTek) and grown 
for 24 h in DMEM with 2.2 mg mL-1 sodium carbonate, 10% fetal bovine serum, 50 μg mL-1 
gentamicin, 50 μg mL-1 penicillin, and 50 μg mL-1 streptomycin at 37 °C and 5% CO2. VLP633-
GFP were prepared in Tris buffer at pH 7.4 (20 mM Tris-HCl, 50 mM NaCl). VLP633-GFP was 
added to cells to a final concentration of 45 nM. Treated cells were further incubated at 37 °C 
with 5% CO2 for 0, 24, and 48 h. After incubation, cells were rinsed three times with PBS. 
Nuclei were stained with Hoechst for 20 min at 37 °C, and washed three times with PBS. Images 
were acquired on a Zeiss LSM 700 Confocal Microscope with 63x oil immersion objective. 
Images were processed with Zeiss Zen software.  
 
 Fluorescence microscopy 3.2.7
To confirm that internalization is not affected by either attachment of fluorescent probes to the 
exterior or in vitro reassembly of VLP, in vivo prepared GFP-containing VLP was added to PC3 
cells to a final concentration of 360 nM and cells incubated without transfection reagent at 37 °C 
and 5% CO2 for 48 h. After incubation, the cells were washed three times with PBS to remove 
residual VLPs. Fluorescence images of PC3 cells were captured using a fluorescence microscope 
(Olympus U-LH100HG, Japan).  
 
 In vitro transcription of RNAilet7 3.2.8
DNA containing the T7 promoter, the RNAilet7, and T7 terminator generated by PCR was used as 
template for in vitro transcription (Primer: RNAi-Fwd and RNAi-Rev, Table S1). The DNA was 
purified with the QIAquick PCR Purification Kit (Qiagen). Approximately 1000 ng of DNA per 
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20 µL reaction volume was transcribed for 4 h at 37 °C with the MEGAscript High Yield 
Transcription Kit (Applied Biosystems), followed by incubation with TURBO DNase for 15 min 
to 1 h at 37 °C. RNA was pelleted by ammonium acetate precipitation, and the pellet was washed 
with 80% ethanol before drying via Speedvac or lyophilization. Pellets were resuspended in 
nuclease-free water and further purified by illustra™ NAP-5™ columns to remove 
unincorporated nucleotides.  
 
 In vitro dicer RNAi scaffold  cleavage assay 3.2.9
Dicer cleavage assay was performed follow the kit protocol. Ten-microliter reactions including 
recombinant human dicer enzyme (1 Unit) and in vitro transcribed RNAi scaffold (RNAilet7, 1 
µg) were incubated at 37°C for 16 h. Reactions were stopped by adding Dicer Stop Solution. In 
vitro Digested samples were directly analyzed by 16% denaturing urea gel. Images were 
acquired using Typhoon™ FLA 9500 biomolecular imager (GE Healthcare).  
 
 In vitro gene transfection GFP inhibition studies 3.2.10
To test for GFP inhibition in HeLa and U87 glioma cells, 12-well plates were seeded with ~ 2 x 
105 cells per well and incubated 24 h before transfection. Cells (HeLa or U87) were transfected 
with GFP-expressing plasmid, gWiz-GFP, carried out by adding 1 μg of gWiz-
GFP/lipofectamine 2000 complexes to each well. After incubation for 18 h at 37 °C and 5% CO2, 
the media was removed, cells washed three times with DI-water to remove residual media, and 
then wells were filled with fresh media. Transgene expression was tested by fluorescence 
microscopy, western blot, and flow cytometry. To test GFP inhibition efficiency, different 
concentration of VLP or VLP-RNAiGFP was added to GFP-expressing cells and cells incubated 
 52 
without transfection reagent at 37 °C for 48 h. After incubation, the cells were washed three 
times with PBS to remove residual VLPs. Fluorescence images of cells were captured using a 
fluorescence microscope (Olympus U-LH100HG, Japan). Expression of GFP proteins was 
determined by Western blot to confirm the inhibition efficiency. All images were collected using 
the same parameters.  
 
 Flow cytometry data analysis 3.2.11
The gWiz-GFP transfected HeLa cells were incubated with different concentrations of VLP-
RNAiGFP (45, 90, 180, 270, 360, 540, 720 nM, 50 μL each) or VLP (360, 720 nM, 50 μL each as 
negative control) at 37 °C and 5% CO2 for 24 h and 48 h.  After washing three times with PBS to 
remove residual VLPs, samples were detached, pelleted and resuspended in PBS. Data on 
inhibition of GFP expression was acquired with a BD™ LSR II flow cytometer (BD 
Biosciences), and analyzed using FACSDiva™ software (BD Biosciences). 
 
 Pan-Ras expression western blots 3.2.12
For Western blot analysis, U87 glioma cells were added to 12-well plates, at a density of about 2 
x 105 cells per well, 24 h before transfection. For Pan-Ras expression western blot anaylsis, the 
study was carried out by adding 100 μL of VLP or VLP-RNAilet7g with concentration of 750 nM 
to each well. After incubation at 37 °C and 5% CO2 for 48 h, the media was removed and cells 
washed three times with serum-free DMEM medium to remove residual VLPs before addition of 
750 μL formal DMEM growth medium containing 10% FBS. An additional 24 h incubation 
period was needed for efficient reaction of let-7 inside the cells. Chemically synthesized let-7 
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miRNA without any transfection agent was used as a negative control. Expression of Pan-Ras 
and GFP proteins was determined by Western blot to confirm the inhibition efficiency. 
 
 VLP-RNAilet7 U87 cell in vitro cytotoxicity assay 3.2.13
U87 glioma cells were cultured in DMEM supplemented with 2.2 mg mL-1 sodium carbonate, 
10% fetal bovine serum, 50 μg mL-1 gentamicin, 50 μg mL-1 penicillin, and 50 μg mL-1 
streptomycin at 37 °C and 5% CO2. Approximately 10,000 cells (i.e., 150 μL of a suspension of 
6.67 ˣ 104 cells/mL) were placed in each well of 96-well culture plates and incubated in a 
humidified chamber at 37 °C and 5% CO2 for 24 h. Variable concentrations of samples (62.5, 
125, 250, 500,1000 nM, 50 μL each) were co-cultured with U87 cells without transfection 
reagent and incubated for 24 and 48 h. After 24 or 48 h of incubation, the culture medium was 
removed from plate, and the cells were incubated in 120 μL of XTT solution for 2 hours. 
Subsequently, 100 μL of the XTT solution was removed from each well and transferred to a 96-
well counting plate. The cytotoxicity toward U87 cells in vitro for different time points was 
evaluated by measuring the OD at 490 nm using an ELISA reader. 
 
3.3 Results 
 The CP and RNAi scaffold co-express and assemble into functional VLPs 3.3.1
We have co-expressed Qβ CP and the RNAi scaffold in E. coli. The resulting RNAi scaffold and 
VLPs were purified and analyzed by gel electrophoresis, transmission electron microscopy, and 
dynamic light scattering (Figure 3.3-1). The RNAi scaffold is overexpressed and accumulated in 
E. coli (Figure 3.3-1a, lane 3) and is successfully packaged inside VLPs (Figure 3.3-1a, lane 4, 
red arrow). VLPs also package background RNA from E. coli during the in vivo self-assembly 
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process. We have observed RNAi scaffold read-through product from in vitro transcription 
(Figure 3.3-1b, lane 5, blue arrow), but not from E. coli total RNA and extracted RNA from 
VLPs. By in vitro Dicer cleavage assay, we have demonstrated that the recombinant human dicer 
can cleave in vitro transcribed RNAi scaffold, to produce oligomers ranging from 21-mers to 25-
mers (Figure 3.3-1b, lane 3, black arrows). Packaging of the RNAi scaffold in the capsid does 
not change the morphology of the VLP (Figure 3.3-1c). Externally our VLPs are 
indistinguishable from previous Qβ VLPs.151,165  
 
To further confirm that the RNAi scaffold assembles with Qβ CP in vivo to form functional 
VLPs, we assayed activities of scaffold-containing and control VLPs. RNA sequences inserted 
into the scaffold were directed against well-characterized targets whose expression levels can be 
readily monitored. The targets included green fluorescent protein (GFP) or the oncogenic Pan-
Ras protein. VLP-RNAiGFP (Figure 3.1-1a) is designed to cause degradation of the mRNA of 
GFP. VLP-RNAilet-7 (Figure 3.1-1b) is designed to decrease Pan-Ras expression at the level of 
translation.166 Both of these VLP-RNAis are seen to be active against their targets but do not 
cross react. Control experiments confirm that neither VLPs containing endogenouse E. coli RNA 
nor VLP-RNAi with off-target RNAi are active.  Therefore, the results are most consistent with 
VLP-RNAi activity against specified RNAi targets. 
 
To further confirm that the RNA scaffold assembles with Qβ CP in vivo to form functional 
VLPs, we assayed activities of scaffold-containing and control VLPs. RNA sequences inserted 
into the scaffold were directed against well-characterized targets whose expression levels can be 
readily monitored. The targets included green fluorescent protein (GFP) or the oncogenic Pan-
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Ras protein. VLP-RNAiGFP (Figure 3.1-1a) is designed to cause degradation of the mRNA of 
GFP. VLP-RNAilet-7 (Figure 3.1-1b) is designed to decrease Pan-Ras expression at the level of 
translation.166 Both of these VLP-RNAis are seen to be active against their targets but do not 
cross react. Control experiments confirm that neither the VLP alone nor non-specific VLP-RNA 
is active.  Therefore, the results confirm that VLP-RNAi are active against RNAi targets, and 




Figure 3.3-1 Characterization of the RNAi scaffold and Qβ-VLPs by electrophoresis, 
microscopy, and dynamic light scattering. (a) The in vivo transcribed RNAi scaffold was 
subject to electrophoresis on a 10% denaturing urea gel. Lane 1: ladder, Lane 2: Total E. 
coli RNA before induction of the scaffold and CP. Lane 3: Total E. coli RNA after 
induction, Lane 4: RNA extracted from purified VLPs, Lane 5: RNAi scaffold prepared by 
in vitro transcription (red arrow) with a length of ~98nt. The blue arrow indicates 
terminator read-through product. (b) RNAi scaffold prepared by in vitro transcription, 
processed by the human dicer enzyme (16% denaturing urea gel). Lane 1: siRNA ladder, 
Lane 2: RNAi scaffold (control). Lane 3: RNAi scaffold treated with human dicer. The 
black arrows indicate processed siRNAs ranging from 21-mers to 25-mers. (c) Size 
characterization of Qβ -VLP with RNAi scaffold (gray rectangle) and wild type Qβ -VLP 
(white triangle) by dynamic light scattering. Inset: Transmission electron microscope 
images of Qβ -VLP containing the RNAi scaffold. Scale bar= 50 nm. 
 
 VLPs are taken up by human cells 3.3.2
Finn and coworkers has previously shown that Qβ VLPs decorated with epidermal growth factor 
domain are rapidly internalized (within an hour in their experiments) in epidermoid carcinoma 
cell line A431 by receptor-mediated endocytosis.167 During those relatively short incubation 
times, undecorated Qβ VLPs associate weakly with A431 cells but are not internalized. Here we 
asked if extending the time period allows internalization of undecorated Qβ VLPs.  
 
The results show that undecorated Qβ VLPs, like undecorated MS2 VLPs,168 are internalized by 
human HeLa cervical and PC3 prostate cancer cell lines over 24 to 48 h (Figure 3.3-2). We 
prepared dual-color VLP633-GFP that can be tracked and monitored for cellular internalization 
and distribution, particle integrity, and cargo release using confocal laser scanning microscopy. 
VLP633-GFP fluoresces at two different wavelengths (Figure 3.3-2) due to the presence of GFP 
in the VLP interior and covalent attachment of DyLight 633 on the VLP exterior. Yellow signal 
microscopy indicates intact VLP633-GFP particles, where green GFP and red DyLight 633 
emissions are co-localized. Green emission alone indicates free GFP that has been released by 
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the VLP, presumably upon VLP dissociation. Red emission alone indicates VLP capsid protein 
in isolation of cargo. 
 
The results show VLP633-GFP particles are internalized by the human epithelial cell line HeLa 
cells in a time-dependent manner. The internalization of VLP633-GFP after 48 h of incubation is 
greater than after 24 h (Figure 3.3-2b-c). Yellow fluorescent particles within the cytoplasm 
slowly resolve, over 24 h, into points of distinct regions of green and red emission, indicating 
that the GFP cargo is released from the VLP633-GFP particles. The particles appear to be 
excluded from the nucleus. Experiments show that VLP internalization is not affected by 
attachment of fluorescent probes to the exterior (Figure 3.3-2b-c and Figure 5.2-1) or by 
packaging of GFP into the interior of VLPs (Figure 3.3-2b-c, Figure 3.3-2e-f). VLP-GFP 
particles are internalized by human prostate cancer cell line PC3 to the same extent as VLP633-







Figure 3.3-2 The internalization of in vitro - assembled, dual-color VLP633-GFP (panels a-c, 
confocal microscopy) and in vivo - assembled, VLP-GFP (panels d-f, fluorescence 
microscopy) by cancer cell lines. HeLa cells were incubated with VLP633-GFP (100 nM) for 
(a) 0 h, (b) 24 h, and (c) 48 h. VLP conjugated with Dylight 633 is red, GFP is green, and 
VLP633-GFP complexes are yellow due to the co-localization of red and green emissions. 
Green color at 24 h indicates that the VLPs have opened and released the GFP. PC3 cells 
incubated with VLP-GFP (360 nM) for 48 h show (d) nuclei, (e) GFP-containing VLPs, and 
(f) merged fluorescent signals. Scale bar (a-c) = 20 µm or (d-f) = 300 µm. The nuclei are 
stained blue with DAPI. 
 
 The RNAi scaffold is functional upon delivery by VLP 3.3.3
VLP-RNAiGFP targets GFP mRNA in HeLa cells. A 22 base pair duplex containing a sequence 
from GFP mRNA was incorporated into the RNAi scaffold (RNAiGFP, Figure 3.1-1a). RNAiGFP, 
was transcribed in E. coli expressing CP, and packaged into VLPs in a single step. To assay their 
activity, the VLPs were purified and co-cultured with HeLa cells transfected with GFP-
expressing plasmid.  
 
GFP expression is inhibited by VLP-RNAiGFP. Incubation of the transfected U87 cells with VLP-
RNAiGFP decreases expression of GFP, as shown by fluorescence microscopy (Figure 3.3-3a-d) 
and western blot analysis (Figure 3.3-3e). The results show VLP-RNAiGFP  can efficiently inhibit 
expression levels of GFP by incubation in 300 nM of VLP-RNAiGFP for 48 h (Figure 3.3-3d and 
3.3-3e, lane 4). High concentrations of VLPs containing endogenous RNAs from E. coli, which 
lack sequences that target GFP mRNA, do not affect GFP expression (Figure 3.3-3c and Figure 
3.3-3e, lane 3). These experiments confirm that inhibition is caused by the VLP-RNAiGFP 
complexes, but not VLP. 
 
This experiment was repeated with the HeLa cells, where similar levels of inhibition of GFP 
expression were observed (Figure 5.2-4). VLP-RNAiGFP induces dose-dependent and time-
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dependent inhibition of GFP expression. Levels of inhibition of GFP expression in HeLa cells 
were analyzed quantitatively by flow cytometry (Figure 5.2-5). For cells transfected with GFP-
expressing plasmid in the absence of VLP-RNAiGFP, 23% of cells fluoresce after 24 h and 21% 
fluoresce after 48 h. In transfected cells that were also treated with 45 nM of VLP-RNAiGFP, 15% 
fluoresce after 24 h and 10% fluoresce after 48 h. The results indicate fluorescence in 50% of 
cells expressing GFP is inhibited by 360 nM of VLP-RNAiGFP after 48 h.  
 
 VLP-RNAilet-7 targets the 3’UTR of Ras mRNA in U87 cells 3.3.4
We constructed a version of the RNAi scaffold containing a sequence from let-7 mRNA (Figure 
3.1-1b). The RNAilet-7 was transcribed and assembled in E. coli with CP to form VLP-RNAilet-7. 
Pan-Ras expression is suppressed by VLP-RNAilet-7 (Figure 3.3-4). U87 cells were treated with 
purified VLP-RNAilet-7 and assayed for Pan-Ras expression. Expression levels of Pan-Ras were 
significantly reduced (>70%) by incubation in 750 nM of VLP-RNAilet-7 for 48 h (Figure 3.3-4a, 
lane 1 and 3). The observed decrease of expression is similar to that observed after treatment 
with chemically synthesized let-7 siRNA associated with a transfection agent (Figure 3.3-4a, 
lane 2). The effect of let-7 siRNA associated with a transfection agent was demonstrated 
previously.169 Our results indicate that VLP-RNAilet-7 is taken up by U87 cells and that functional 
RNAilet-7 is released from the VLP to trigger RNAi. We have also performed a series of control 
experiments that minimize the chance that RNAi is caused here from off-target effects. Pan-Ras 
expression levels from U87 cells are unaltered by VLPs containing endogenous E. coli RNA or 
by VLP-RNAiGFP (Figure 3.3-4a, lane 4 and 5). These control experiments are most consistent 
with a model in which activity of VLP-RNAilet-7 arises from the expected mechanism.  
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 VLP-RNAilet-7 attenuates U87 cell proliferation and promotes cell death 3.3.5
Cell viability decreases in a time and dose-dependent fashion consistent with delivery of  
RNAilet-7 (Figure 3.3-4b). We confirm previous work169 showing that chemically synthesized let-
7 miRNA alone was not functional in the absence of a transfection reagent.  We investigated the 
viability of U87 cells upon treatment with VLP-RNAilet7 and  VLP-RNAiGFP (control) for 24 and 
48 h. VLP-RNAilet-7 promotes U87 cell death in a dose-dependent and time-dependent manner as 
observed for GFP inhibition. The concentration required for 50% inhibition of growth (IC50) for 
VLP-RNAilet-7 is greater than 1000 nM after 24 h of incubation but is only 202 nM when the 
incubation period is extended to 48 h. The extended time for function presumably arises in part 
from the time-dependence of processes downstream of Ras expression or the processing of the 
VLP to release RNAilet-7 scaffold. Control experiments confirm that cell death is caused by the 





Figure 3.3-3 Suppression of gene expression by VLP-RNAiGFP in human glioblastoma cell 
line U87. Cells were treated with (a) PBS, (b) Transfection agent along with a plasmid 
expressing GFP, (c) Transfection agent/plasmid expressing GFP followed after 18 hours by 
treatment with 300 nM VLPWT (negative control containing endogenous E. coli RNA), (d) 
Transfection agent/plasmid expressing GFP followed after 18 hours by treatment with by 
300 nM of VLP-RNAiGFP. (e) Western blot analysis of GFP expression. Lane 1 shows the 
GFP expression in the cells corresponding to panel (a). Lane 2 shows expression in panel 
(b). Lane 3 shows expression in panel (c). Lane 4 shows expression in panel (d). In the 
images, green shows GFP expressions; blue shows nuclei. Images were obtained 48 hours 





Figure 3.3-4 VLP-RNAilet-7 inhibits Pan-Ras expression and demonstrates in vitro 
cytotoxicity in U87 cells. (a) Western blot analysis of Pan-Ras levels in U87 after 48 h with 
no treatment (lane 1), chemically synthesized let7 RNA delivered by the transfection agent 
lipofectamine (lane 2), VLP-RNAilet-7 (lane 3), VLP (lane 4) and VLP-RNAiGFP (lane 5). U87 
cells were incubated with 750 nM VLP in the absence of transfection reagent for 48 h. (b) 
Cell viability of VLP-RNAilet-7 and VLP-RNAiGFP. U87 cell viability was determined after 
treatment with various concentrations of VLP-RNAilet-7 for 24 h (●) and 48 h (▼) and VLP-
RNAiGFP for 24 h (■) and 48 h (▲). The level of viability of U87 cells is reported here as 
percentage survival. Values are expressed as means ±SD (n = 8). 
 
3.4 Discussion 
We have designed a general utility RNAi scaffold that spontaneously assembles with CP to form 
functional VLP-RNAi. The scaffold is a single RNA molecule containing the Qβ hairpin on the 
5’ end, a carrier strand, the miR-30 stem loop, and the silencing strand. The RNAi scaffold is 
designed to promote unimolecular pairing of the carrier and silencing strands, and contains a 3’ 
terminus appropriately placed to direct dicer to release the single-stranded silencing strand. This 
RNAi scaffold can contain a broad variety of silencing sequences including miRNAs and 
siRNAs that can target essentially any mRNA. As a single RNA molecule, the scaffold folds 
efficiently, and readily assembles with CP to form Qβ VLPs containing functional RNA. 
Advantages of the VLP-RNAi system we describe here include ease of vector construction, 
assembly and packaging, purification, targeting and delivery, and in effectiveness of regulating 
gene expression.  
Previous work identified a variant of human miR-30 that maximizes production of mature 
miRNA, and demonstrated function of RNAi in human cells by substituting the stems of miR-30 
with artificial targeting sequences.158 Ramratnam incorporated a siRNA sequence targeting the 
mRNA of HIV-1 transactivator protein tat into the miR-30 stem. The resulting artificial miRNA 
is 80% more potent in reducing target p24 antigen production than conventional tat shRNA.159 
The enhancement of gene silencing may be due in part to high stability of the miR-30 stem-
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loop.170 The miR-30 stem-loop provides a tool for intramolecular folding of shRNA, which is 
rapid and efficient, whereas formation of an intermolecular duplex by RNAs in unlinked strands 
is less efficient.171  
 
We placed Qβ hairpin on the 5’ end of scaffold, following Stockley, who synthesized a 
bimolecular aptamer-siRNA.168 Our design of the RNAi scaffold presents a free 3’ end for 
recognition by the PAZ domain of Dicer 164,172 and efficient transfer of the processed siRNA to 
Argonaute.172 To facilitate one-step VLP-RNAi assembly in E. coli and to maximize activity, we 
co-express CP and cargo RNA,151 which contains the packaging aptamer (the Qβ hairpin),168 
stabilizing the scaffold with miR-30.158 The RNAi scaffold and Qβ CP were placed under control 
of T7 RNA polymerase promoters and are co-expressed in E. coli. The Qβ CP is transcribed and 
translated, packaging the transcribed RNAi scaffold, spontaneously forming functional VLPs in 
vivo. The assays and controls indicate that the RNAi scaffold is packaged within the VLPs.   
 
We have incorporated several silencing sequences into the RNAi scaffold (Figure 3.1-1) and 
demonstrated function of these VLP-RNAi in a variety of human cell lines. The VLP-RNAi’s 
inhibit expression of a reporter gene encoding GFP or expression of the Pan-Ras oncogene.  
GFP expression in HeLa and U87 cells is inhibited by VLP-RNAiGFP (Figure 3.3-3). The VLP-
RNAiGFP induces dose-dependent and time-dependent inhibition of GFP expression. The effect is 
specific: high concentrations of VLPs containing other RNAs do not decrease the level of GFP 
expression (Figure 3.3-3, Figure 5.2-4 and Figure 5.2-5).  
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Pan-Ras expression is suppressed by VLP-RNAilet-7 (Figure 3.3-4). VLP-RNAilet-7 attenuates U87 
cell proliferation, promotes death in cell culture and down regulates Pan-Ras. Let-7 miRNAs 
function as tumor suppressors by decreasing expression of the Ras oncogene family at the level 
of translation,166,173 reducing cell proliferation and invasion. Down-regulation of let-7 has been 
observed in lung cancer, colon cancer, and melanoma and is correlated with poor patient 
survival.174-177 Restoration of let-7 expression may be a useful cancer therapy.177 Ras proteins (K-
Ras, N-Ras and Pan-Ras) are known to be up-regulated in these cancers.178 Human Ras 
expression is regulated by let-7 miRNA by binding to the 3’ UTR of Ras mRNA.166 In human 
brain tumor cells, overexpression of let-7 miRNA leads to a decrease in Ras protein expression, 
inhibition of cell proliferation and reduced tumor growth, without harming normal astrocytes.179  
 
Our control experiments confirm that Qβ VLPs containing non-specific RNAs are non-
functional and benign. VLP-RNAi is active only when the RNAi scaffold contains functional 
RNAi sequences. In sum, the results show that the in vivo packaged VLP-RNAi containing the 
RNAi scaffold is efficient in inhibiting gene regulation and in promoting tumor cell death. The 
combined results demonstrate that undecorated Qβ VLPs enter cell lines in the absence of 
transfection reagent and surface decoration. Our results, along with earlier studies, demonstrate 
extended incubation times, allowing internalization of undecorated MS2168 and Qβ VLPs. These 
results extend prior work in which surface decoration facilitates uptake of MS2 VLPs and Qβ 
VLPs in mammalian cells.152,180-182 Previously, several groups showed that when surfaces of Qβ 
and the closely related MS2 VLPs are decorated with appropriate targeting ligands, the VLPs are 
quickly internalized by human cells via receptor-mediated endocytosis.152,167,180,181,183 Stockley 
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showed that undecorated MS2 VLPs are also internalized, but more slowly.168 Once internalized, 
VLPs disassemble and release their cargo, which is functional in vivo (in cell culture).148,152,168 
 
Control and functional assays confirm that VLPs release their cargo intracellularly (Figures 3.3-
3, 3.3-4, and Figures 5.2-5). Previous work has reported similar cytoplasmic release from 
bacteriophage MS2 VLPs.152,168,180,182,184 The mechanism by which VLP-encapsidated RNA 
escapes from the endosome and enters cytoplasm remains unclear. Our results are consistent with 
previous work which show that ssRNA animal viruses can pass their viral genomes to the 
cytoplasm from the endosomes.185  
 
The release mechanism of RNA from the VLP is most likely a combination of disulfide bond 
breakage and destabilization by low pH. Reducing agents such as glutathione that are important 
antioxidants in cells. The low pH in late endosomes and lysosomes may dissociate the coat 
proteins of the Qβ-VLPs. A combination of the above phenomena may result in the escape of 
encapsidated nucleic acid.  
 
The efficiency of VLPs for delivering cargos to human cells depends on targeting, VLP uptake 
and endosome escape. Finn and Stockley both showed that covalent attachment of targeting 
peptides facilitates VLP uptake in human cell lines in short time periods at less than 50 
nanomolar concentrations.167,168,182 In addition, covalent attachment of a histidine-rich fusogenic 
peptide on the exterior surface VLPs can promote endosomal escape of internalized VLPs.152 
This histidine-rich peptide acts by a “proton sponge” effect. Histidine can sequester protons and 
buffer the acidification in the endosomes. The buffering induces osmotic swelling and bursting 
 69 
of endosomes.186,187 Impressively, the working concentration of siRNA-loaded VLPs with 
covalent attachment of both targeting and fusogenic peptides is less than 150 pM.152 Comparison 
of our work with the results of several other groups who have decorated the MS2 or Qβ VLP 
external surface with different targeting ligands, suggests that undecorated VLP-RNAi requires 
higher concentrations and longer incubation times. Increasing the efficiency of VLP uptake and 




































44. USING CATIONIC QΒ VLPS FOR CO-DELIVERY OF DNA PLASMID 
AND PACKAGING RNA 
 
4.1 Introduction & Motivation 
 
Over the past 10 years, virus-like particles (VLPs) have been considered as new bio-
nanoparticles, and have emerged as potential tools for therapeutic delivery and cell imaging.188 
VLPs are well known for their stability under thermal stress and various pH conditions, 
resistance to proteolytic degradation, and ease of surface modification.4,18,24 Previous reports 
with peptide display on the exterior surface of VLPs demonstrated cell-specific delivery.15,18 
Toxin molecules and siRNA molecules can be loaded into VLPs using in vitro packaging method 
for delivery to specific cancer cells and achieve maximum cell death and gene silencing.15,189 
Previous studies have shown delivery of in vivo produced VLPs containing fluorescent proteins 
to mammalian cells.23,190 We have designed a general utility RNAi scaffold that is able to co-
assemble with Qβ coat proteins into VLPs in E. coli (Chapter 3.3-1). The Qβ VLP-RNAi 
platform has shown promising RNAi-mediated inhibition of target gene in mammalian cells 
(Chapter 3.3-3 and 3.3-4).  
 
Besides RNAi-based therapeutic strategies, DNA gene therapy is another potential solution to 
genetic disorders and cancer. Plasmid DNA-based gene therapy with a suicide gene encoding 
thymidine kinase has demonstrated inhibition of tumor growth in mouse models.191 The use of 
plasmid DNA vaccine has also shown promising results in the protection against human 
papillomavirus (HPV).192 Although Qβ VLPs are extremely versatile bio-nanoparticles, the 
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VLPs originated from single-stranded RNA (ssRNA) bacteriophages (e.g., Qβ and MS2), and are 
not capable of packaging plasmid DNA in vitro and in vivo due to their natural limits. 
 
Plasmid DNA delivery is usually accomplished by either viral vectors or cationic polymers. In 
general, viral vector systems (e.g., retroviruses and adenoviruses) show greater efficiencies for 
cellular delivery and gene expression, compared to non-viral mediated systems.81 However, 
several safety concerns of viral vector systems regarding immunological response, specificity of 
transgene delivery, and unwanted mutagenesis must be addressed.86 Non-viral alternatives have 
become increasingly in demand.  
 
Many cationic polymers such as poly(β-amino esters) (PAEs), poly (L-lysine) (PLL), and 
poly(ethyleneimine) (PEI) are widely used as advance strategies to interact negatively charged 
phosphate backbone of DNA and RNA for nucleic acid delivery.193,194 For example, PEIs have 
been designed as plasmid DNA carriers for cancer gene therapy (e.g., bladder, ovarian, and 
pancreatic cancer), and have been studied under clinical evaluation.195 PAEs have been 
developed as an aerosol siRNA delivery system and show significant anticancer activity with 
low toxicity in lung tumor-bearing mice.196  
 
Cationic polymers are composed of primary, secondary, and tertiary amine functional groups. 
Primary and secondary amines are strong nucleophiles that allow for covalent conjugation of 
different functional molecules to polymers with specific crosslinking agents  (e.g. EDC/NHS or 
sulfo-SMCC).197,198 At the physiological pH range, amines in cationic polymers are generally 
protonated and carry positive charges. The resulting protonated amines allow complexation of 
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polymers with anionic nucleic acids through electrostatic interaction 81,82 and are capable of 
inducing the proton sponge effect to enhance endosomal escape.194,199 In addition, nanoparticles 
carrying positive charge, show higher cellular uptake efficiency than uncharged or negatively 
charged ones.200-202 
 
Based on previous studies and current research in nucleic acid delivery, we report here a new 
delivery approach for the simultaneous delivery of DNA and RNA by combining cationic 
polymers and Qβ VLP (Figure 4.1-1). The method employs surface modification of RNA-
containing VLPs that decorates by covalent conjugation of PEIs. The PEI-VLP (pVLP) 
complexes occur in vitro and form homogeneous particles with a positively charged surface. Our 
initial investigation shows that pVLP exhibits efficient DNA delivery in mammalian cells. We 
have successfully co-delivered plasmid DNA with Qβ VLP containing in vivo packaged RNA.  
Our results may provide a new insight into VLPs originated from the ssRNA bacteriophage as a 
DNA delivery systems. We believe this co-delivery strategy of plasmid DNA and functional 













Figure 4.1-1 Preparation of plasmid DNA loaded RNA-containing VLPs. 
 
4.2 Materials & Methods 
 Reagents 4.2.1
DNA oligos were ordered from Eurofins MWG Operon, Inc. NZY broth media was purchased 
from TEKNOVA. Sec-Butanol and Chloroform were purchased from Fisher Scientific. 
Ammonium sulfate was purchased from ICN Biomedicals. Sucrose, RNase- and DNase-free, 
was purchased from Amresco. Dithiothreitol (DTT) was purchased from Research Products 
International Corp. N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), N-
Hydroxysuccinimide (NHS), 2-(N-Morpholino)ethanesulfonic acid, 4-Morpholineethanesulfonic 
acid (MES), amd Cy®5 NHS ester were purchased from Sigma-Aldrich. Sodium dodecyl sulfate 
was purchased from Shelton Scientific, Inc. Polyethylene glycol 8000 was purchased from J. T. 
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Baker. 30% hydrogen peroxide was purchased from Fisher Scientific. BCA protein assay kit was 
purchased from Thermo Scientific. Polyallomer centrifuge tubes were purchased from Beckman 
Coulter. Amicon® Ultra centrifugal filters (100 kDa MWCO) were purchased from Millipore. 
Spectra/Por® dialysis tubing (15 KDa MWCO) was purchased from Spectrum® Laboratories, 
Inc. All other reagents were analytical grade.  
 
 Construction of Qβ CP expression vector 4.2.2
DNA encoding Qβ CP monomer (NCBI reference sequence: NC_001890.1) was synthesized by 
recursive-PCR (R-PCR)121 and cloned into pCDF-1b (Novagen) to generate plasmid pCDF-CP 
previously. All constructs were sequence confirmed (MWG Operon). 
 
 Expression of Qβ VLP-RNA complexes 4.2.3
 
E. coli containing pCDF-Qβ CP vector was inoculated in NZY medium with streptomycin 
(50µg.mL-1) and incubated overnight at 37°C. Qβ-VLP production started with the addition of 
1% overnight culture to the ZYM-5052 auto-induction medium 123. Production culture was 
incubated 24 h at 37°C. Cells were collected by centrifugation at 4°C and 6500xg for 30 min. 
Cells were resuspended in equal volume of Qβ buffer (10 mM MgCl2 and 20 mM Tris-HCl, 
pH7.5) and lysed by sonication at 40 watts for three min with 10s on/off intervals. The lysate 
was centrifuged to remove cell debris for 30 minutes at 23,430xg. 2M Ammonium sulfate 
precipitation followed by 30-minute centrifugation at 23,430xg was performed to obtain crude 
VLP. Crude VLPs were then suspended in 1 mL Qβ buffer and extracted with 1:1 n-
butanol:chloroform. Organic extraction was repeated three times. The aqueous layer was 
subsequently purified by step sucrose gradient ultracentrifugation (10-40% w:v) in a SW41Ti 
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rotor (Beckman) at 40K RPM for two hours. Qβ VLPs were precipitated from the sucrose 
fraction with 20% (w/v) PEG8000. Resuspended Qβ-VLPs were combined and dialyzed against 
2 L dialysis buffer (20 mM Tris, pH 7.5 and 50 mM NaCl) for 2 h. This procedure was repeated 
three times prior to the use of particles in further analyses.  
 
 Preparation of cationic VLP-Cy5 complexes 4.2.4
The purified RNA-containing VLPs were mixed with NHS-mediated Cy5, and vortexed for two 
hours at 4°C in the dark. Cy5 immobilized on the surface of VLPs (VLPs-Cy5) was separated 
from the solution and washed with DI water. Cationic VLPs-Cy5 complexes were prepared by 
conjugation of PEI on the surface of VLPs-Cy5. Briefly, ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC, 12 mg) and sulfo-N-hydroxysulfosuccinimide sodium salt 
(sulfo-NHS, 27 mg) were dissolved in 2 mL of 0.5 M 2-(N-morpholino) ethanesulfonic acid 
(MES) buffer at pH 6.3) in the dark. A 0.1 mL aliquot of the above solution was mixed with 0.1 
mL of a 45 µM VLPs-Cy5 at 25°C and reacted for 30 min in the dark then further mixed with 0.1 
mL of PEI with different concentrations (i.e., 0.2 w/w% and 0.5 w/w%) for another three hour at 
4°C in the dark to form pVLPs-Cy5. The produced pVLPs-Cy5 complexes were purified by 
Amicon® Ultra centrifugal filters (100 kDa MWCO) and suspended in PBS (pH = 7.4) for 
storage or 25 mM sodium acetate (pH = 5.4) for loading DNA plasmid. 
 
 Fluorescence microscopy 4.2.5
HEK 293 cells (2 x 105 cells) were seeded into glass bottom microwell dishes (MatTek) and 
grown for 24 h in DMEM with 2.2 mg mL-1 sodium carbonate, 10% fetal bovine serum, 50 μg 
mL-1 gentamicin, 50 μg mL-1 penicillin, and 50 μg mL-1 streptomycin at 37 °C and 5% CO2. 
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Cationic VLPs-Cy5 complexes were added to cells to a final concentration of 1.25 μM. Treated 
cells were further incubated at 37 °C with 5% CO2 for 0, 24, and 48 h. After incubation, cells 
were rinsed three times with PBS. Nuclei were stained with Hoechst for 20 min at 37 °C, and 
washed three times with PBS. Fluorescence images of HEK 293 cells were captured using a 
fluorescence microscope (Olympus U-LH100HG, Japan).  
 
4.3 Results 
 Strategies for conjugating branched PEI to Qβ VLP.  4.3.1
Here, we initially investigated the conjugation of branched PEI (Figure 4.3-1a) to RNA-
containing VLPs. The molecular weight (Mn) of PEI is up to 5,000 by gel permeation 
chromatography (GPC), relative to polystyrene standard. Carboxyl groups on the exterior surface 
of Qβ VLP (e.g., side chains of aspartic acid and glutamic acid and the C-terminus) are used to 
conjugate primary amine of branched PEI with zero-length crosslinking agents, carbodiimide and 
sulfo-N-hydroxysuccinimide (EDC and sulfo-NHS) in vitro. The conjugation of PEI to the 
exterior surface of VLPs proceeded in one step in 0.5 M MES buffer at pH 6.3 with EDC and 
sulfo-NHS at 4°C for 12 h (Figure 4.1-1, step 1). There are 12 carboxylic acid groups in each 
coat protein (CP) monomer (Figure 4.3-1b). We predict that less than four carboxylic groups 
react to branched PEI in each CP monomer due to steric hindrance. This effect may limit the 























Figure 4.3-1 Structure of branched PEI and possible conjugation sites in CP dimer (a) 
Synthesized PEI used in this study. (b) Location of carboxylic acid in a Qβ CP dimer. 
Cartoon representation shows the structure of Qβ CP dimer. Carboxylic groups from 
aspartic acid, glutamic acid, and the C-terminus are highlighted in a stick representation.  
 
 Characterization of PEI-conjugated VLPs 4.3.2
Branched PEI was conjugated to the Qβ VLPs to form cationic bio-nanoparticles. The resulting 
pVLPs were subjected to dynamic light scattering, native agarose gel electrophoresis, and 
denaturing SDS-PAGE (Figure 4.3-2). Different degrees of PEI conjugation (0.1, 0.2, 0.5, and 
1.0 wt% of PEI solution) to VLPs were analyzed. Conjugation of the PEI on the RNA-containing 
VLP increases the range of zeta potential from -2.8 ± 0.8 mV (wild-type) up to 14.3 ± 1.2 mV 
(0.2 wt% PEI solution). Conjugation of VLPs to higher concentration of PEI (0.5 wt% and 1 
wt% PEI solution) exhibit moderate expansion in the diameter of capsid from 31.2 ± 1.7 nm 
(wild-type) to 43.1 ± 1.0 nm (1 wt%) at pH 7.4 (Figure 4.3-2a). We have not observed particle 
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aggregation after preparation of RNA-containing pVLPs. To further confirm that conjugated 
VLPs carry positive charges, we analyzed gel mobility for RNA-containing pVLPs and control 
wild-type VLPs. The results obtained from native agarose gel demonstrate that the mobility of 
pVLPs was retarded towards anode, relative to wild-type RNA-containing VLPs (Figure 4.3-2b). 
pVLPs with higher degree of PEI labeling (0.5 wt% PEI solution) do not migrate, remaining in 
the wells of the gel. The denatured SDS-PAGE results show smeared CP monomer bands 
appeared in both lower and higher (0.2 wt% and 0.5 wt% PEI solution) degree of labeling, but 
not in wild-type VLPs (Figure 4.3-2c). The protein band at 28 kDa represents CP dimers 
remaining noncovalently associated as noted previously.203,204 The combined results suggest that 
RNA-containing VLPs have been successfully conjugated to branched PEI and carry positive 
































Figure 4.3-2 PEI is conjugated to the exterior surface of VLPs to form cationic VLP 
complexes. (a) Size and zeta potential of RNA-containing pVLPs and wild-type RNA 
containing VLPs by dynamic light scattering. Values are expressed mean ± SD (n=3). 
pVLPs and VLPs were subject to electrophoresis on (b) a native 1.2% agarose gel and 
visualized with GelStarTM, and (c) a 12.5% denatureed SDS-PAGE and stained with 
Coomassie blue. Lane 1: conjugated Qβ-VLPs using 0.5 wt% PEI solution, Lane 2: 
conjugated Qβ-VLPs using 0.2 wt% PEI solution, Lane 3: purified Qβ-VLP without PEI 




 The Plasmid DNA is expressing upon delivery by cationic VLPs 4.3.3
Cationic RNA-containing pVLPs deliver plasmid DNA into cultured human cells. To prove the 
pVLPs with plasmid DNA could be efficiently co-delivered to cells, the RNA-containing pVLPs 
were modified with Cy5 on the surface for tracking and monitoring. A 5.7 kb plasmid DNA 
encoding green fluorescent protein (GFP) was incubated with pVLP-Cy5 particles to form 
plasmid DNA loaded pVLP-Cy5 complexes (Figure 4.1-1, step 2). Cy5-labeled cationic VLPs 
(pVLP-Cy5) were prepared using PEI as mentioned above. Here, we asked cationic pVLP-Cy5 
allow adsorption, delivery and release of plasmid DNA. The green and red fluorescent signals 
are observed after 48 h of co-culture using fluorescent microscopy. After incubation of 48 h with 
pVLP-Cy5, the cells exhibited red and green fluorescent signals, indicating that the pVLP-Cy5 
was taken up into cells and then released plasmid DNA from plasmid loaded pVLP-Cy5 
complexes to expression of GFP protein within the cytoplasm. The results indicate that plasmid 
DNA is adsorbed and delivered by cationic VLPs and is expressing in human embryonic kidney 
293 cells (HEK293) (Figure 4.3-3). It implies cationic VLPs could be used as delivery vehicles 





Figure 4.3-3 Cationic pVLP-Cy5 complexes can deliver and release plasmid DNA encoding 
GFP in cells. HEK293 cells were incubated with plasmid DNA loaded cationic pVLP-Cy5 
complexes (1.25 µM) for 48 h. VLP conjugated with Cy5 is red, and GFP is green. Green 
color at 48 h indicates that the plasmid DNA has been released from particles. The nuclei 
are stained blue with DAPI. 
4.4 Discussion 
Here, we demonstrated an approach for co-delivery of plasmid DNA and RNA-containing VLPs. 
Commercially available branched PEI was used to conjugate on the exterior surface of Qβ VLPs 
to investigate the effects of cationic polymer on adsorption, delivery and release of plasmid DNA 
(Scheme 4.3-1). Our preliminary results indicate that conjugation of RNA-containing VLPs to 
cationic PEI polymer leads to an increase of the zeta potential from -2.8 ± 0.8 mV up to 14.3 ± 
1.2 mV and an increase in the hydrodynamic diameter from 31.2 ± 1.7 nm to 43.1 ± 1.0 nm 
(Figure 4.3-2). We also show that adsorption of plasmid DNA on the surface of VLPs provides 
gene delivery and expression in mammalian cells (Figure 4.3-3).  
 
Several groups have packaged foreign plasmid DNA into VLPs by in vitro methods and then 
delivered to eukaryotic cells.205-207 By using this in vitro method, VLP disassembly and 
reassembly are required to achieve foreign plasmid DNA packaging into particles. Recently, JC 
virus-like particles (JC VLPs) originated from a double stranded DNA virus have been utilized 
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successfully to simultaneously package foreign plasmid DNA that was co-expressed in the E. 
coli.208 The maximum size of foreign plasmid DNA packaging by JC VLPs in E. coli is up to 9.4 
kilobases (kb).209 The plasmid DNA-filled JC VLPs carrying the suicide gene have demonstrated 
efficient exogenous gene delivery to tumor cells and inhibition of tumor growth.191  
 
Finn, et al, has recently demonstrated that Qβ VLPs incorporating the unnatural amino acid are 
able to conduct polymerization in the interior space of VLPs by atom-transfer radical 
polymerization.203 The work shows that the cationic polymers inside a RNA-free VLPs offer 
substantial positive charge of the particles. Most importantly, the siRNA molecules may either 
be adsorbed on the surface of VLPs, or they may enter the particle to perform siRNA delivery 
into HeLa cells.  
 
Our initial proof-of-concept experiments used an alternative method to combined natural 
biopolymer and synthetic cationic polymer to form cationic VLPs. The effects of an increasing 
PEI concentration during surface conjugation on particle size and surface charge were 
investigated. The particle size of VLPs increases linearly with increasing concentration of PEI. 
However, the zeta potential of RNA-containing pVLPs increases linearly with increasing 
concentration of PEI until it reaches a plateau between 0.2 wt% and 1 wt% PEI (Figure 4.3-2a). 
It suggests that conjugation of carboxylic acid group on the exterior surface of VLPs reaches the 
maximum at 0.2 wt% solution of PEI. When a higher wt% of PEI solution is used during the 
process of conjugation, excess amount of unreacted PEI molecules may accumulate on VLPs via 
non-covalent interaction to cause size expansion. This sterically crowded surface is likely to 
prevent exposure of the cationic amine groups on the exterior surface of VLPs. We have 
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observed two conjugated VLPs (0.2 wt% PEI vs. 0.5 wt% PEI) with similar zeta potentials 
seeing no results in similar migration pattern on native agarose gel (Figure 4.3-2b). The results 
indicate the size of both PEI conjugated VLPs is different which is consistent with data from 
dynamic light scattering experiments. Qβ coat protein monomer extracted from PEI conjugated 
VLPs streaks slightly to higher molecular weight on SDS-PAGE as previously observed (Figure 
4.3-2c).8,203 Detailed size characterization of RNA-containing pVLPs may be performed by 
transmission electron microscopy and size-exclusion chromatography. 
 
RNA-containing pVLPs are capable of delivering and releasing plasmid DNA into mammalian 
cells (Figure 4.3-3). The image results from fluorescence microscopy demonstrated co-delivery 
of plasmid DNA encoding a green fluorescent protein and pVLP-Cy5 particles. The expression 
of green fluorescent protein in the cytoplasm indicates plasmid DNA adsorption and desorption 
on cationic pVLP-Cy5 particles. Maximum adsorption capacity of PEI-conjugated VLPs will be 
further investigated.  
 
The hybrid pVLP system we developed here shows ease of plasmid DNA adsorption onto 
positive charged VLPs, plasmid DNA delivery for foreign gene expression. Ultimately, we 
would like to combine this pVLP system with our RNAi scaffold to achieve co-delivery of 







55. RECOMMENDATIONS AND CONCLUSIONS 
 
5.1 Recommendations 
 Multiple RNAi target in single VLP 5.1.1
As shown in Chapter 3, VLP-RNAi is capable of inhibiting mRNA translation of a single target 
in cancer cell culture. One of the goals of future work proposed here is to target multiple genes 
by in vivo produced VLP-RNAi complexes. We will develop new RNAi scaffolds that can 
silence multiple target genes. This new RNAi scaffold is inspired by a non-coding RNA (pRNA 
ring) derived from bacteriophage phi29.210 The pRNAs assemble into three-membered or six-
membered nanoparticles without covalent linkage and crosslinking. Previous studies have shown 
RNAi activity induced by pRNA/siRNA chimera in vitro and in vivo.211-213 The self-assembly of 
pRNAs provide substantial stability to urea denaturation.211 The new RNAi scaffold we designed 
can carry different target siRNAs and self-assemble into stable RNA nanoparticles. The RNA 
nanoparticles with Qβ hp can then be encapsulated into Qβ VLP. We will systematically 
determine the optimum RNA length, and RNA structure for efficient RNAi and self-assembly. In 
addition, we will design, construct and test RNA constructs with RNA aptamer for affinity 
purification.  
 
 Continued development of multifunctional VLP for brain cancer  5.1.2
As shown in Chapter 4, Error! Reference source not found.we have introduced a method to 
o-deliver DNA plasmid through a cationic polymer-VLP system (pVLP). The second proposal is 
to improve our multifunctional VLPs for brain tumor research. Brain tumor is one of the most 
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lethal cancers due to difficulties of delivering therapeutic agents across blood-brain barrier 
(BBB) and serious side effects. To overcome this hurdle, we propose a self-assembled VLP with 
cationic polymers and targeting ligands as multifunctional nanocarriers to deliver RNAi 
molecules, chemotherapeutics, suicide gene expression plasmid, and green fluorescence proteins 
(GFP) for RNA interference, gene therapy and imaging tracking. Qβ coat proteins and cargos 
including RNAi molecules and fluorescent proteins will be produced and self-assembled in E. 
coli. Previous study has shown APOE incorporated lysosomal enzymes enables delivery across 
the BBB.214 The cationic polymer and APOE-peptide would be incorporated to the exterior 
surface of VLPs to carry DNA plasmid DNA on the exterior surface, enhance cellular uptake, 
and promote BBB penetration.  
 
Our collaborator Dr. Hung-Wei Yang’s group at the National Sun Yat-sen University, Taiwan 
has assessed pVLP by cell examination. pVLPs with APOE-peptide do not show cytotoxicity 
and can be internalized inside brain tumor cells efficiently. Based on these studies and our 
current finding, it is reasonable to propose in vivo experiments to confirm that APOE peptide-
VLP conjugates can facilitate the crossing of BBB. We also expect to knockdown 
bioluminescence reporter gene in the brain of a transgenic mice model to confirm the efficiency 
of BBB penetration and protein inhibition. The ultimate goal is to deliver multifunctional VLPs 
against brain tumor growth in mice. We believe this multifunctional VLPs platform has potential 
to overcome impediments mentioned earlier and is well suited for nucleic acid-based tools. 
 
5.2 Conclusions 
We have made significant progress in solving RNA packaging, protection, and delivering 
functional RNA using VLPs. We have discovered ways to optimize packaging efficiency of 
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target RNAs in VLPs. We found RNA structure and Qβ hairpin to be the prevailing factor 
affecting the efficiency of non-viral RNA packaging within VLPs. The presence of a ribosome 
binding site (RBS) or absence of the Qβ hairpin sequence in the RNA affects packaging 
efficiency. We have shown that VLPs stabilize RNA and attenuate RNA degradation from high 
concentrations of Mg2+ ions, hydroxyl radicals generated from Fe2+ ions mediated Fenton 
chemistry, and nucleases (Chapter 2).  
 
We have also designed and constructed VLP-RNAs containing novel chimeric RNA cargo and 
demonstrated functional RNA interference with target gene expression in HeLa and U-87 cancer 
cells. Other results, including direct confocal visualization of fluorescently tagged VLPs, and 
activity assays with VLP-RNAis, show that VLPs are readily taken up by a variety of human 
cells and perform RNA interference (Chapter 3).  
 
We have demonstrated that PEI conjugated VLP complexes can be loaded with DNA plasmid on 
the exterior surface. We have shown that DNA plasmids can be adsorbed on the surface of PEI 
conjugated VLP complexes. DNA plasmids are spontaneously dissociated from VLP complexes 
and can drive target gene expression in the intracellular environment (Chapter 4).  
 
This dissertation developed a number of VLP applications for target gene regulation and 
expression. Gene regulation can be achieved by in vivo produced VLP-RNAi complexes. Gene 
expression can be accomplished through pVLP-DNA plasmid complexes. Regardless of the 
function, the packaging efficiency of in vivo non-viral RNA to Qβ VLP in the field of 
recombinant RNA production makes this Qβ VLP system worthwhile investigating.  
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Appendix A 
SUPPLEMENTARY INFORMATION FOR CHAPTER 2 
A.1 Sequences 
Table 5.2-1 Qβ coat protein primers and oligos used for coat protein gene construction by 
recursive PCR. Restriction sites are underlined: 1) CP-Fwd is the forward primer, which 
contains an NcoI site; 2) CP-Rev is the reverse primer, which contains an AvrII site. 
Primer or oligo 
name  
DNA sequence 
CP-Fwd 5’- GTG GCC ATG GCA AAT TAG AGA CTG TTA CTT -3’ 
CP-Rev 5’- CAC CCC TAG GTC AAT ACG CTG GGT TC -3’ 
QβCP-F1 5’- GTG GGC TCA GCT CAA TAC GCT GGG TTC AGC TGA TCA 
ATA GCA TCG ATC AGC AGA GGA CTA -3’ 
QβCP-R1 5’- GCT TTT GTT CGT ACA GAG CTT GCT GCT CTG CTC GCT AGT 
CCT CTG CTG ATC GAT GCT ATT -3’ 
QβCP-F2 5’- GCA AGC TCT GTA CGA ACA AAA GCT CGT TCC TCA TCG 
GTA CTA TAC TGC GTG AAC GAA AAG GTC -3’ 
QβCP-R2 5’- TTG TGA CCC ATC CGT TAC TCG CCA GGC ATA TGC TGA 
CGT GAC CTT TTC GTT CAC GCA GTA TAG TA -3’ 
QβCP-F3 5’- CGA GTA ACG GAT GGG TCA CAA GAA CCG TTT GCA GTG 
CAA GCG GTC GGG TTC TGG ATC TTA ACC TGG ACC -3’ 
QβCP-R3 5’- CCG TTT CGG TAT CTC AGC CTT CTC GCA ATC GTA AGA 
ACT ACA AGG TCC AGG TTA AGA TCC AGA ACC -3’ 
QβCP-F4 5’- AAG GCT GAG ATA CCG AAA CGG TAA CAC GCT TCT CCA 
GCG CAG GAA CTG CAC CCG CTT GTG AAA GCG-3’ 
QβCP-R4 5’- TCT GGT CCT CAA TCC GCG TGG GGT AAA TCC CAC TAA 
CGG CGT TGC CTC GCT TTC ACA AGC GGG TG -3’ 
QβCP-F5 5’- ACG CGG ATT GAG GAC CAG AGT TTG TTT TCC ATC TTT 
CCC GAT GTT ACC TAA AGT AAC AGT C -3’ 
QβCP-R5 5’- CAC CCC ATG GGC AAA ATT AGA GAC TGT TAC TTT AGG 
TAA CAT CGG GAA -3’ 
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Table 5.2-2 The Primers and oligos used for corresponding non-viral RNA gene 
construction. a) The Qβ hp is highlighted in blue. b) The spacer region highlighted in pink 
italics. c) The ribosomal binding site (RBS), highlighted in red. d) Overlapping 
recombinant RNA fragments, including a-rRNA, 23S rRNA, and GFP mRNA are 





Primer or oligomer sequence  
a-rRNA-hp FWD 5’- GTG GTC TAG AGT CCG AGT AAT TTA CGT TTT GA -3’ 
a-rRNA-hp REV 5’- GGT GGC TCA GCG CGA AGA TGC TGT -3’ 
a-rRNA-hp oligo F1 5’- TCT AGA GTC CGA GTA ATT TAC GTT TTG ATA CGG 
TTG CGG AAC TTG CGG GGT GCC TAT TGA AGC ATG -3’ 
a-rRNA-hp oligo F2 5’- TCT CTA TCC GCC ACG GGC TTC CTC GTG CTT AGT 
AAC TAA GGA TGA AAT GCA TGT C -3’ 
a-rRNA-hp oligo R2 5’- GCT CAG CGC GAA GAT GCT GTC TTA GAC ATG CAT 
TTC ATC CTT AGT TAC TAA GC -3’ 
 
23S rRNA-hp hpa,b,c,d,e 
 
Primer or oligomer sequence 
23S rRNA-hp FWD 5’- GTG GTC TAG AGT CCG AGT AAT TTA CGT TTT GA -3’ 
23S rRNA-hp REV 5’- GGT GGC TCA GCG CGA AGA TGC TGT -3’ 
23S rRNA-hp oligo F1 5’-TCT AGA GTC CGA GTA ATT TAC GTT TTG ATA CGG 
TTG CGG AAC TTG C -3’ 
23S rRNA-hp oligo R1 5’- GCA TCC ACC GTG GGC CCT TAC CAT CTT GAC GCA 
AGT TCC GC AAC CGT AT C -3’ 
23S rRNA-hp oligo F2 5’- CCG AGG TCT TGA CCC CTC CTT CCT CGT GCT TAG 
TAA CTA AGG ATG AAA TG -3’ 
23S rRNA-hp oligo R2 5’- GCT CAG CGC GAA GAT GCT GTC TTA GAC ATG CAT 




Primer or oligomer sequence 
mRNAGFP-hp FWD 5’- GTG GTC TAG AAT GGC TAG CAA AGG AGA AGA 
ACT CT -3’ 








Primer or oligomer sequence 
RBS-mRNAGFP-hp FWD 5’- GTG GTC TAG A AT GGC TAG CAA AGG AGA AGA 
ACT CT -3’ 
RBS-mRNAGFP-hp REV 5’- GGT GGC TCA GCG CGA AGA TGC TGT -3’ 
RBS-mRNAGFP-hp oligo 
F1 
5’- TCT AGA ATA ATT TTG TTT AAC TTT AAG AAG GAG 




Primer or oligomer sequence 
a-rRNA FWD 5’- GTG GTC TAG AGT CCG AGT AAT TTA CGT TTT GA -3’ 
a-rRNA REV 5’- GGT GGC TCA GCG CCC GTG GCG GAT AGA GA -3’ 
 
Appendix B 
SUPPLEMENTARY INFORMATION FOR CHAPTER 3 
B.1 Sequences 
Table 5.2-3 Qβ coat protein, GFP, and RNAi scaffold primers used for production 
of GFP-containing VLPs and functional VLP-RNAi particles. Restriction sites are 
underlined: 1) CP-Fwd: NcoI; 2) CP-Rev: AvrII; 3) GFP-Fwd: BglII; 4) GFP-Rev: 
BlpI; 5) RNAi-Fwd: BglII; 6) RNAi-Rev: XhoI. 
Primer name Primer sequence 
CP-Fwd 5’-GTGGCCATGGCAAATTAGAGACTGTTACTT-3’ 
CP-Rev 5’-CACCCCTAGGTCAATACGCTGGGTTC-3’ 


















Table 5.2-4 The RNAi scaffold sequences used for GFP and Pan-Ras protein 
inhibition. T7 promoter and T7 terminator are noted in italics; Qβ RNA hairpin is 
noted in blue; stem and stem-loop derived from miR-30b is noted in green; targeting 
































B.2 Supplemental Data 
1. Characterization of VLP-GFP uptake by human cells (Figure 5.2-1) and in vivo 
packaging of GFP in VLP (Figure 5.2-2 and 5.2-3) 
 
Qβ VLP647 lacking internal GFP enters DU-145 cells (Figure 5.2-1). In addition, co-
expression of Qβ CP and GFP in E. coli produces GFP-containing VLPs (Figure 5.2-2). 
GFP is spontaneously packaged within the VLPs to levels sufficient to confer observable 
fluorescence (Figure 5.2-3), eliminating the need for in vitro packaging. These VLP-
GFPs are internalized by PC3, human prostate cancer cells (Figure 3.3-2e-f) to similar 
extents with or without attachment of fluorescent probes on the surface (Figure 3.3-2b-c). 
Previous studies showed that in vivo packaging of GFP in VLP is mediated by RNA 
aptamers.215 Here we show GFP packaging in VLP simply by expressing GFP and CP in 











Figure 5.2-1 The internalization of VLP647 by DU-145 cells: DU-145 cells were 
incubated with VLP647 (100nM) for 24 h. Images were taken by confocal 
microscope. (a) DyLight-conjugated VLP, (b) bright field (c) nuclei, (d) merged 
confocal signals. The nuclei are stained blue with DAPI. VLP conjugated with 






Figure 5.2-2 Characterization of in vivo prepared GFP-containing Qβ-VLPs with 
electrophoresis. The purified Qβ-VLP was analyzed by 10% SDS-PAGE. The 
molecular weight of Qβ CP monomer is 14.5 kDa. Lane 1: ladder, Lane 2: Qβ CP 
monomer from purified wild-type Qβ-VLP, Lane 3: in vivo –prepared, GFP-
containing Qβ-VLPs. The molecular weight of GFP (A) is 28.3 kDa. Undefined E. 




Figure 5.2-3 Characterization of in vivo prepared, GFP-containing Qβ VLPs by 
sucrose density gradient ultracentrifugation. E. coli produced GFP-containing VLPs 
form a discrete layer of green fluorescence signal after ultracentrifugation. The 
wild-type VLPs (control) do not have a fluorescent layer. Image was taken under 













2. RNAi activity of in vivo VLP-RNAiGFP assembly (Figure 5.2-4 and 5.2-5) 
Qβ-CP and RNAiGFP were co-expressed in E. coli to spontaneously assemble functional 




Figure 5.2-4 Suppression of gene expression by VLP-RNAiGFP in HeLa. HeLa cells 
were treated with (a) PBS, (b) GFP-expressing plasmid, (c) VLP-RNAiGFP after GFP 
-expressing plasmid transfection, or (d) VLP after GFP-expressing plasmid 
transfection. Cells were incubated with 360 nM VLP-RNAiGFP or VLP in the 
absence of transfection reagent for 24 h. The images were taken 24 h after addition 
of VLP-RNAiGFP. In the images, green spots indicate cell with GFP expression; blue 




Figure 5.2-5 Inhibition of GFP expression in HeLa cells quantified by flow 
cytometry. (a) HeLa cells; (b) HeLa cells transfected with GFP expressing plasmid 
alone; (c) HeLa cells transfected with GFP expressing plasmid co-cultured with 
VLP-RNAiGFP; (d) HeLa cells transfected with GFP expressing plasmid co-
cultured with VLP. P2 represents the fluorescent signal of GFP. The negative 
control is VLP that does not contain RNAiGFP. (e) Gene expression levels of GFP in 
HeLa cells were determined after treatment with various concentrations of VLP-
RNAiGFP for 24 h (white) and 48 h (grey). The GFP gene expression levels are 
reported here as percentage of fluorescence positive cells. The negative control is 
VLP that does not contain RNAiGFP. Values are expressed as means ±SD (n = 3). 
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The in vivo transcribed RNA scaffold content of each VLP could not be quantified by 
analytical ultracentrifugation (AUC), since E. coli tRNAs, mRNAs, and rRNAs were 
encapsided in VLPs as well. Stockley has shown that MS2 VLPs reassemble in vitro with 
MS2 coat protein and an RNA conjugate (TR-siRNA) by AUC. The TR-siRNA 
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